



(51) International Patent Classification:

A61K 38/18 (2006.01) A61P 17/02 (2006.01)
A61P 17/00 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/EP2018/070712

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

31 July 2018 (31.07.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17183990.5 31 July 2017 (31.07.2017) EP

(71) Applicant: ACCANIS BIOTECH F&E GMBH & CO
KG [AT/AT]; Karl-Farkas-Gasse 22, 1030 Vienna (AT).

(72) Inventors: MANDLER, Markus; c/o Accanis Biotech
F&E GmbH & Co KG, Karl-Farkas-Gasse 22, 1030 Vienna
(AT). MATTNER, Frank; c/o Accanis Biotech F&E
GmbH & Co KG, Karl-Farkas-Gasse 22, 1030 Vienna (AT).
SCHMIDT, Walter; c/o Accanis Biotech F&E GmbH &
Co KG, Karl-Farkas-Gasse 22, 1030 Vienna (AT). SCH-
NEEBERGER, Achim; c/o Accanis Biotech F&E GmbH
& Co KG, Karl-Farkas-Gasse 22, 1030 Vienna (AT).

(74) Agent: SONN & PARTNER PATENTANWÄLTE;
Riemergasse 14, 1010 Vienna (AT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF LOCAL SKIN HYPOTROPHY CONDITIONS

(57) Abstract: The invention discloses Fibroblast growth factor 2 (FGF2) and Fibroblast growth factor 7 (FGF7) messenger-RNA (mRNA), wherein the mRNA has a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region, a 3' untranslated region (3'-UTR) and a poly-adenosine tail (poly-A tail), for use in the treatment of local skin hypotrophy conditions and kits for administrating this mRNA to a human patient in need thereof.



Treatment of local skin hypotrophy conditions

The present invention relates to compositions and methods for the treatment of local skin hypotrophy conditions characterized by an hypotrophic state of one or several skin layers, especially atrophic skin conditions and atrophic scars.

The present invention relates to compositions and methods for the treatment of skin disease resulting in a hypotrophic state ("hypotrophy") of one or several skin layers (epidermis, dermis subcutaneous fat), especially atrophic scars, as medical indications, but also skin conditions that are associated with skin ageing, which are generally regarded as cosmetic problems and areas of interest (Fitzpatrick's Dermatology in General Medicine, 6th edition, Editors Freedberg et al., Chapter 144 in Fitzpatrick's Dermatology in General Medicine by Yaar et al.: Aging of Skin; Photodamaged skin, editor: Goldberg, chapter 5 by Wheeland: Nonmalignant clinical manifestations of photodamage; Skin Aging editors: Gilchrest et al., Springer, ISBN-10 3-540-24443-3; Therapie der Hautkrankheiten, Editors: Orfanos et al.).

Hypotrophy of skin and atrophic scarring are widely prevalent skin conditions. Specific diseases that are associated with hypotrophy/atrophy of the skin include cutis laxa, acrodermatitis chronica atrophicans, atrophoderma idiopathica et progressiva Pasini Pierini, scars resulting from perforating dermatoses, atrophy blanche, necrobiosis lipoidica, radiation dermatitis (skin changes resulting from exposure to ionizing radiation), striae cutis distensae (caused by pregnancy, rapid growth, alimentary obesity). The spectrum extends from small reductions in the volume of given skin layers to a complete tissue loss, its maximal variant. Tissue loss could be restricted to the epidermal compartment (i.e. erosion) or could include the dermal and/or subcutaneous compartment, then called ulcer. Causes for skin ulcers are numerous and include trauma, autoimmune-pathological pathology, reduced perfusion (arterial or venous), psychogenic injury (self-trauma), infections. Specific diseases include ulcerative dermatitis as a result of bacterial infection, ulcerative sarcoidosis, ulcerative lichen planus, diabetic foot ulcer, ulcer associated with high blood pressure, ulcer associated with venous insufficiency, neuropathic ulcer, pressure sore, vasculitis (small and medium size vessels), pyoderma gan-

graenosum, rheumatioid ulceration, necrobiosis lipoidica, drug-induced necrosis (e.g. caused by warfarin, heparin), ulcers in the context of coagulopathies (e.g. caused by antiphospholipid syndrome, protein S deficiency).

Atrophic scars manifest primarily on the face, chest and back of patients. It most commonly results from acne and chick-enpox, but also from surgery, infections, drugs (e.g. steroid injection, penicillamine), autoimmunological processes (e.g. chronic discoid lupus erythematosus), trauma, nerve- and psychogenic (e.g. acne excoriée de jeunes filles) injuries. Hypotrophic/atrophic areas do not constitute an acute/active wound or active site of tissue remodeling but constitute an end-result of inefficient and aberrant repair mechanisms following a local tissue insult. In case of atrophic scars, the decreased dermal volume results in a downward pull of the affected skin area causing a sunken appearance.

Scars differ from wounds in that they are the end outcome of the natural wound healing process. Wounds represent a stage after an insult that is characterized by active repair and remodeling processes. The natural wound healing process has come to an end when the wound is closed (epithelialized) and the tissue is remodelled. This typically results in a defective state compared to the pre-lesional (non-insulted) situation. The persistent defect is more pronounced in atrophic scars compared to normal scars.

WO 2015/117021 discloses methods for delivering RNAs through the skin for expedited wound healing and treatment of scarring (including bFGF) but does not mention or propose FGFs for use in situations where the wound healing process has come to an end, i.e. in scars, especially atrophic/hypotrophic scars.

This is further indicated in Examples 38, 50, and 51 in WO 2015/117021, which teach the use of growth factors like basic fibroblast growth factor (FGF2) for changing the wound healing process and the process leading to the formation of a scar (scarring). No effect on already existing scars is proposed.

Cutaneous aging falls into two categories: intrinsic (occurs with the passage of time and is predetermined by genetic predisposition) and extrinsic (largely the result of chronic sun damage (UV B and UV A); other contributing extrinsic factors in-

clude infrared radiation and tobacco smoke) aging. Clinical manifestations include dryness (roughness), irregular pigmentation, wrinkling/rhytides, dermatohelios (severe deep wrinkling), leathery skin appearance, stellate pseudoscars, fine nodularity, inelasticity, teleangiectasias, purpura (easy bruising), comedones (maladies Favre et Racouchot) sebaceous hyperplasia and neoplasias (e.g., actinic keratosis, basal cell carcinoma, squamous cell carcinoma). Pathophysiologically, skin hypo-/atrophy exhibits characteristic changes within the epidermal, dermal or subcutaneous compartment. Pathological changes in the former includes little change in epidermal thickness, keratinocyte shape and corneocyte cohesion. Major change is observed in the dermoepidermal junction, which is flattened resulting in a reduced surface contact between the epidermis and the dermis (reduced exchange of nutrients and metabolites). The dermis is hypocellular with reduced numbers of fibroblasts, mast cells and reduced dermal volume. Collagen fibers become loose and there is a moderate thickening of elastic fibers. In addition, there is a decrease in blood vessels with an associated shortening of capillary loops.

Early and effective treatment of hypotrophic and atrophic tissue is thus paramount for both, medical indications and cosmetic areas. An estimated 1% of the adult population has persistent atrophic/hypotrophic scars from adolescence, of which, 1 in 7 is considered to have disfiguring scars. The appearance of atrophic scars worsens with age due to the natural lipoatrophy of the skin. Facial scarring is strongly associated with psychological trauma in many patients, including loss of self-esteem, increased difficulty in obtaining employment and a diminished quality-of-life (QOL). In addition, clinical studies have revealed that facial scarring, particularly in men, has been correlated with depression and suicidal intention.

A broad array of therapeutic interventions, targeting the different skin compartments affected, have been developed over the past few decades to treat localised skin hypotrophy and atrophic scars, most notably application of ablative lasers, autologous fat transfer, and chemical peelings (reviewed in Patel et al., J. Roy. Soc. Med. Open 5 (2014), 1-13; DOI: 10.1177/2054270414540139). However, these treatments are highly-operator dependent and may have long recovery times (reviewed in

Hession et al., J. Clin. Aesthet. Dermatol. 8 (2015), 50-58). Although laser therapy is considered to be the gold standard for treatment, it is usually not effective enough on its own to achieve adequate results for disfiguring scars. In reality, patients usually require the use of several different treatment techniques over multiple session in order to achieve the desired effect, increasing time and treatment costs. Therefore, there is a high unmet medical need for a potent, inexpensive atrophic scar treatment modality.

Current therapeutic interventions for hypotrophic skin areas and atrophic scars are not effective enough on their own to achieve adequate results, requiring the use of multiple treatment options, increasing time and treatment costs. In addition, most of these therapeutic interventions rely on iatrogenic wounding of the skin area to be treated, including treatment with ablative lasers and the various peeling procedures. All of them finally trigger the cascade of events generally known as wound healing processes. For obvious reasons, their efficacy is limited by the biological age of a given individual.

To increase the results of the treatment, often various approaches are combined to relatively complex treatment regimens. For example, Kang and colleagues presented a triple combination therapy combining dot peeling and subcision, done twice 2-3 months apart, and fractional laser irradiation, which was performed every 3-4 weeks, to obtain an approximately 55% improvement in scar severity. A double combination included a derma roller and 15% TCA peel performed alternatively at 2-weeks interval for 6 sessions to see an improvement of 1 grade on an international scar assessment scale. Obviously, rational combination therapies are based on the complementarity of the approaches to be combined, and, therefore, limited in their number. Moreover, their scientific and clinical evaluation is complex and their efficacy appears to be limited for technical and biological reasons.

Beside these applications, there is a long list of trials trying to topically apply different growth factors (GFs), also including fibroblast growth factors like FGF2 and FGF7, as proteins or DNA expression plasmids in order to enhance skin repair in situations with ulcers/erosions due to disease processes or following wounding or iatrogenic measures such as treatment with

ablative lasers, dermabrasion, etc. These GFs (including platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor- β (TGF- β), epidermal growth factor (EGF), granulocyte colony-stimulating growth factor (G-CSF), keratinocyte growth factor (KGF), interleukin 6 (IL-6), interleukin 8 (IL-8), and hepatocyte growth factor (HGF) etc.) are normally involved in various steps of wound healing. Studies done to elucidate their potential in wound healing and tissue remodeling in experimental preclinical systems and patients demonstrated only limited success.

For example, application of growth factors as proteins showed only very limited efficacy in vivo due to various reasons. GFs are secreted proteins with short half-lives. In addition to this highly limiting factor, it has been shown by extensive analyses that only a fraction of topically applied GFs is able to penetrate the skin, possibly via sweat glands in the interfollicular stratum corneum. A clinical study investigated dermal remodeling following twice daily application of GF serum (NouriCel-MD, TNS recovery complex, Allergan, containing cell culture medium collected from a line of dermal fibroblasts originating from neonatal foreskin) for 60 days. It was found that 78.6% of patients showed clinical improvement after 60 days. Processing of punch biopsies demonstrated that only 37% of patients with clinical improvement were found to have new collagen formation and even less, 27% of the treated population, showed epidermal thickening (Fitzpatrick et al., J. Cosmet. Laser Ther. 5 (2003), 25-34). A second vehicle controlled, double-blind study using the same GF serum also showed very limited improvement in fine wrinkles and skin tone (Mehta et al., J. Drugs Dermatol. 7(2008), 864-71).

The preliminary effects of topically applied GFs as proteins suggest that they could have a much greater efficacy on skin remodeling in case their local availability was significantly improved.

US 2014/199367 A1 discloses a topical transdermal method for delivering nutrients (proteins, amino acids, nucleic acids) through the skin for expedited wound healing and skin rejuvenation but does not mention FGFs or any specific nucleic acids.

WO 2012/106508 A1 discloses a method for treating and/or preventing keloids or hypertrophic scars by injecting modified

oligonucleotides into the affected injured skin.

WO 00/59424 A1 discloses grafting of a porous pad comprising wound healing factors such as growth factors, e.g. bFGF, for promoting wound healing in mammals.

US 2012/264690 A1 discloses a method for preventing incisional hernia formation and acute wound failure by administering a composition comprising basic fibroblast growth factor.

US 2013/0095061 A1: discloses a composition for application to the skin for the prevention or treatment of an adverse skin condition, the composition comprising elastase 2A; prostaglandin I2; prostaglandin E2; amphiregulin; fibroblast growth factor 2; fibroblast growth factor 7; G protein-coupled receptor, family C, group 5, member B; and GABA(a) receptor-associated protein like 1.

WO 2016/100820 A2 discloses a method of reducing blood glucose by administering mutated FGF2 protein or nucleic acids encoding the mutated FGF2 protein or a vector comprising the nucleic acid for the treatment of metabolic diseases e.g. diabetes.

Dou Chunqing et al. (Mol Ther. 22(4)(2014): 752-761) describes a gene delivery approach to strengthen structurally fragile skin, e.g. atrophic skin in paraplegic patients or healed chronic wounds in diabetic patients, by topical application of a DNA plasmid expressing KGF-1 (FGF7) after microdermabrasion.

Marti et al. (Gene Ther. 11(24)(2004): 1780-5) discloses improved and accelerated wound healing of cutaneous wounds in diabetic mice upon intradermal injection of KGF-1 plasmid DNA in combination with electroporation.

Lin et al. (Wound Repair Regen. 14(5)(2006): 618-24; J. Am. Coll. Surg. 199 (2004), 58-59) discloses improved and accelerated wound healing of cutaneous wounds in septic rats upon intradermal injection of KGF-1 plasmid DNA in combination with electroporation.

In US 2002/071834 A1, augmentation of wound healing by EIF4E mRNA and EGF mRNA is disclosed.

US 2010/221232 A1 discloses compositions for osteogenic gene therapy increasing bone growth and enhancing wound healing, e.g. fracture repair, the compositions comprising recombinant nucleic acids encoding FGF-2.

None of the GFs analysed and tested so far, including FGF2 and FGF7, are currently used in clinical practice to treat wounds or, as suggested by the current invention, hypotrophic skin and atrophic scars.

These unimpressively low success rates of recombinant protein and DNA based therapies so far in wound healing as well as the lack of strategies for treatment of hypotrophic skin and atrophic scars warrant the development of novel treatment paradigms to meet the medical need in the treatment of hypotrophic skin and atrophic scars.

It is an object of the present invention to provide improved treatment methods for local skin hypotrophy, atrophic skin conditions and atrophic scars which (at least partially) overcome the limitations of current treatment options summarized above. It is a further object that such improved treatment schemes provide improved patient's compliance and improved adverse reaction events. A further object of the present invention is to provide methods which are easily reversible and do not have severe impact on the patient's body as a whole (i.e. (adverse) systemic consequences due to the treatment). Moreover, it is a desire to provide growth factor treatment without the normally accompanied burden for the patients and to increase treatment efficiency, responder rates and patient compliance.

Therefore, the present invention provides Fibroblast growth factor (FGF) messenger-RNA (mRNA), wherein the mRNA has a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region, a 3' untranslated region (3'-UTR) and a poly-adenosine Tail (poly-A Tail), for use in the treatment of local skin hypotrophy conditions, especially atrophic skin conditions, wherein the FGF mRNA encodes for FGF2 and/or FGF7.

The present invention aims to treat and prevent the indications listed by activating a specific milieu that normally stimulates skin repair only in an acute remodeling process, for example due to wounding, inflammation or burns. Importantly, the tissue area aimed to be treated is devoid of these activating and remodeling stimuli before application of the intended treatment modality and is considered to be healthy skin.

The present invention allows e.g. local administration on or into the skin of patients suffering from local skin hypotrophy conditions, especially atrophic skin conditions.

The present invention is centered around the treatment of local skin hypotrophies in general and specifically aims at the treatment of atrophic scars. The treatment according to the present invention therefore takes place at a timepoint when wound healing processes have already taken place, i.e. often significantly later than the end of wound closing and healing (sometimes weeks, months or years after the wound healing process). Accordingly, the issues and skin conditions in the treatment of hypotrophies are significantly different from the prerequisites of wound closure and wound healing processes.

Accordingly, the present invention is applicable for all conditions in which dermal tissue is reduced (i.e. local hypotrophy conditions, especially also selected from the group consisting of *cutis laxa*, *acrodermatitis chronica atrophicans*, *atrophoderma idiopathica et progressiva Pasini Pierini*, scars resulting from perforating dermatoses, *atrophy blanche*, *necrobiosis lipoidica*, *radiation dermatitis*, *striae cutis distensae*, atrophic skin conditions, glucocorticoid (GC)-induced skin atrophy, atrophic scars and skin ulcer). In such conditions the invention aims at increasing the local dermal volume by e.g. expression of elastin or extracellular matrix components thereby creating an alleviation of the volume deficit and resulting in treatment of local skin hypotrophies.

Along these lines skin hypotrophy conditions comprise areas of sunken skin in a place where damage was previously inflicted upon but healing is completely resolved. Of course, it is conceivable for a man skilled in the art that according to the present invention atrophy is considered an increase compared to hypotrophy in a local skin area. Accordingly, both forms represent a permanent loss of dermal and possibly subcutaneous tissue as compared to healthy, non hypotrophic/atrophic skin areas with atrophic conditions showing a more pronounced reduction than hypotrophic conditions.

Hypotrophic skin conditions also especially comprise atrophic skin conditions; for example, atrophic scars and GC-induced skin atrophy are considered as a subgroup of atrophic skin conditions. The extent and number of atrophic lesions is thereby more or less pronounced, depending on the underlying pathophysiologic changes: for atrophic scars, for example for injury related atrophic scars these are usually just localized

to one side of the face whereas acne induced atrophic scars are usually localized on both cheeks.

There is no generally accepted clinical scale that would grade atrophic scars according to their depth/severity. This is based on the fact that severity does always have a subjective note. Factors that determine the peculiarity of an atrophic scars/atrophic scars beyond depth are their size, colour and localization. That is to state that scars with only a minimal and hardly visible depth are to be regarded as hypotrophic/atrophic.

The first fibroblast growth factor (FGF) ligands, FGF1 and FGF2, were initially purified from brain as mitogenic factors of fibroblasts grown in culture. Since their discovery, FGF ligands and their receptors have been implicated in numerous biological processes, and their dysregulation causes several congenital diseases (such as dwarfism) and some types of cancer. In addition to their mitogenic capacity, FGFs can also modulate cell survival, migration and differentiation in culture. Members of the FGF family of extracellular ligands are characterised by a conserved core of 140 amino acids and their strong affinity for heparin sulphate (HS). The molecular weight of FGFs range from 17 to 34 kDa in vertebrates, whereas it reaches to 84 kDa in *Drosophila*. In vertebrates, 22 family members have been identified and are grouped into seven subfamilies according to their sequence homology and function (Ornitz, *BioEssays* 22 (2000), 108-112); e.g.: FGF1 and FGF2 (FGF1 subfamily); FGF4, FGF5 and FGF6 (FGF4 subfamily); FGF3, FGF7, FGF10 and FGF22 (FGF7 subfamily); FGF8, FGF17 and FGF18 (FGF8 subfamily); FGF9, FGF16 and FGF20 (FGF9 subfamily); FGF11, FGF12, FGF13 and FGF14 (FGF11 subfamily); FGF19, FGF21, and FGF23 (FGF19 subfamily)). All FGFs, with the exception of the intracellular FGFs 11-14, signal through a family of tyrosine kinase receptors, the FGF receptors (FGFRs). Secreted FGF ligands bind the extracellular domain of the FGFRs and this leads to dimerisation of the receptor (FGF-FGFR-HS dimers) resulting in the transphosphorylation of intracellular tyrosine residues. This triggers the activation of cytoplasmic signal transduction pathways, such as the Ras/ERK/MAPK pathway (which is associated with proliferation and differentiation), the Akt pathway (associated with cell survival) or the protein kinase C (PKC) pathways (involved in cell morphology and migration). Except for one subfamily, all FGFs exhibit high-

affinity binding to heparans and HS, and thus exert paracrine control in areas adjacent to their secretion. Only the FGF-19 subfamily, including FGF-21, FGF-23, and FGF-19 in humans and the mouse FGF-19 equivalent, FGF-15, acts in an endocrine fashion and require the Klotho gene family of transmembrane proteins as coreceptors to bind their cognate FGF receptors and exert their biological activities.

FGF7, also known as Keratinocyte growth factor (KGF, FGF7), was first isolated as an epithelial mitogen from the conditioned medium of human embryonic lung fibroblasts. FGF7 is primarily produced by cells of mesenchymal origin and is well known to strongly activate FGFR2b, so far, no other activity towards any other FGFR isoform has been detected. The restricted pattern of FGFR2b expression primarily in epithelial cells and the high specificity of FGF7 for this FGFR isoform support the hypothesis that they function as paracrine signals mediating mesenchymal-epithelial communication. Loss of function mutations of FGF7 in mice only leads to minor alterations in hair characteristics, kidney development and urothelial stratification in the bladder, indicating that FGF7/KGF does not play a critical role in developmental organogenesis. Experiments analysing FGF7 function rather imply, that the main role of FGF7/KGF is centered around regulation of epithelial preservation and/or repair processes. The beneficial effects described for FGF7/KGF activity in acute insults arises from multiple mechanisms that act synergistically to strengthen tissue integrity (mainly epithelium) by stimulating processes like cell proliferation, - migration, - differentiation, and - survival. Accordingly, FGF7/KGF has been the subject of intensive efforts to identify clinical applications in which the preservation or rapid restoration of epithelial tissues would be of benefit. Currently, a truncated form of recombinant FGF7/KGF (palifermin, marketed as Kepivance) has been approved for the treatment of severe oral mucositis in patients with hematologic malignancies prior to autologous blood progenitor cell transplantation.

FGF7/KGF was also shown to be upregulated following tissue damage in skin (mouse and human full-thickness wounds). Based upon such observations, experiments were performed with FGF7/KGF in animals to determine whether its topical application to the skin could stimulate epidermal wound repair. Importantly, the

magnitude of these effects exerted by protein application was not considered sufficient to warrant clinical development.

Fibroblast growth factor 2 (FGF2), a prototypic member of the FGF family, is encoded by a single gene. However, alternative translation-initiation codons and polyadenylation signals produce various isoforms (Touriol et al., *Biol. Cell.* 95 (2003), 169-178). Low molecular weight FGF2 (Lo FGF2) is an 18 kDa protein translated from a conventional AUG start codon and its 155 amino acid sequence is common to all FGF2 isoforms (Ibrahimi et al. 2004). Alternative isoforms (e.g.: 20.5 and 21 kDa) are produced from CUG sites upstream and inframe of the AUG codon. These forms are localized in the nucleus and are responsible for the intracrine effect of FGF2. The RNA Sequence in the CDS of the 18kd form of FGF2 is 468 nucleotides and is an integral part of the naturally occurring full length mRNA sequence as disclosed in a publicly available database with the accession numbers: J04513.1 (<https://www.ncbi.nlm.nih.gov/nucore>). Alternatively, the sequence is also disclosed in NM_002006.4 and M27968.1, respectively. The 21.5kd form has 591 nucleotides in the CDS and encodes 196aa and the CDS of the 22kd form has 633 nucleotides encoding for 210aa. Usage of these CDS variants would also lead to secretion of the short form of FGF2 described in this invention.

The isoforms of FGF2 are expressed in fixed molar ratios that are dependent on tissue type. These ratios are translationally regulated as overexpression of the human FGF2 gene in mice does not alter these ratios in the human FGF2 protein products. High MW FGF2 and low MW FGF2 can potentially associate reciprocally, modulating each other's biological activity depending on their relative ratios and/or localization. FGF2 isoforms are localized differentially and display different gene expression profiles. In response to ischemia/reperfusion (I/R) injury only low MW FGF2 can be released from cardiac cells further indicating the intracrine localization of high MW FGF2. Exported low MW FGF2 binds to the FGF receptor (FGFR) extracellularly and its binding is modulated by nonsignaling heparin/heparan sulphate proteoglycans that are subsequently involved in the intracellular processing of FGF2.

Alternative sequences for FGF2 which have been proposed for use also include changes of the CDS: FGF2 is lacking a standard

secretion signal and export is mediated by an energy-dependent, non-ER/Golgi pathway. Hence, adding of alternative secretion signals within the FGF2 coding sequence have been suggested to increase secretion and are included: Sohn et al. (Sohn et al., *Biochem Biophys Res Commun* 284 (2001): 931-936.) use a classical secretion signal sequence of FGF-4, Sasada et al. (*Ann NY Acad Sci* 638 (1991): 149-160) use the secretion signal sequence of IL-2 (Blam et al., *Oncogene* 3 (1988): 129-136) use the secretion signal sequence of Growth hormone;

In addition, also mutation of the second and third of the four cysteines (i.e., cys-70 and cys-88) to serine and asparagine have been suggested to increase protein stability without affecting the biological activity of FGF2. Accordingly, also a combination of mutations with altered secretion sequences as mentioned above has been suggested as well. Along these lines: Chen et al. (*J. Cell. Biochem.* 100 (2007): 1493-1508 and references therein) suggest the use of BMP, specifically BMP-2/4 hybrid secretion signal sequences along with mutation of the second and third of the four cysteines (i.e., cys-70 and cys-88) to serine and asparagine to increase stability and secretion of the mutated FGF2 protein.

FGF2 is generally considered a potent mitogen and chemoattractant for different cell types, including endothelial cells, fibroblasts and keratinocytes. Among other proposed functions it has been implied that FGF2 stimulates metabolism, can regulate the extracellular matrix (ECM), and also influences the movement of mesoderm-derived cells. FGF2 function is also required for limb and nervous system development and also promotes tumour growth.

Along these lines, several experiments have been performed analysing the potential applicability of FGF2 for wound healing. The administration of recombinant FGF2 to skin wounds could accelerate acute and chronic wound healing in preclinical models. In addition, bFGF-knockout mice showed a delayed healing of skin wounds, which indicates that FGF2 signalling could also be involved in normal wound healing in vertebrates. A potential function in processes other than acute wound healing and associated remodelling however remains elusive.

In general, the clinical success of growth factors administered as recombinant proteins to enhance wound repair and skin

remodelling has been disappointing, despite their apparent efficacy in animal studies. While application of FGF2 and FGF7 has been shown to be effective in acute wound treatment in the pre-clinical arena, it never became a therapeutic option for clinical routine. The reasons are obvious.

Treatment requires frequent (daily with single or multiple applications per day) perilesional injections/applications over several weeks. Also, recombinant protein was expensive and the quality and importantly bioactivity of the preparations differed. FGFs were produced by recombinant DNA technology using genetically engineered *E. coli* strains requiring extensive purification and potency/bioactivity testing in order to provide a comparable level of bioactivity for treatment with varying degree of non-active and active protein in the product.

Furthermore, it has been postulated that the bioactivity of the recombinant proteins is rapidly diminished because of elevated concentrations of matrix metalloproteinases (MMPs) and other myeloid cell derived proteinases present in the wound environment. Furthermore, bolus administration does not keep the protein localized to the wound area and necessitates large amounts of the growth factor(s) that may have harmful side effects such as vascularization of non-target tissues or stimulation of tumour growth. Analysis of two pharmacologically active FGFs, FGF7 and FGF2, respectively, also supports this inability of recombinant protein to act as useful therapeutics (very high doses and limited efficacy due to very fast elimination). The pharmacokinetics of the FGF7 protein Kepivance were studied in healthy subjects and patients with hematologic malignancies. After single intravenous doses of 20-250 µg/kg in healthy subjects and 60µg/kg in cancer patients, Kepivance concentrations declined over 95% in the first 30 minutes post-dosing. The elimination half-life was similar between healthy subjects and cancer patients with an average of 4.5 hours (range: 3.3 to 5.7 hours). No accumulation of Kepivance occurred after 3 consecutive daily doses of 20 and 40 µg/kg in healthy subjects or 60 µg/kg in cancer patients. Similarly, the recombinant FGF2 preparations show a serum half-life of 2.9 min when injected intravenously (Edelman et al., PNAS 90 (1993), 1513-1517).

Alternatively, pharmaceutically active FGF2 is used as Traf-ermin, a recombinant form of FGF2, which is marketed as Fiblast

Spray. Fiblast Spray, the world's first recombinant human bFGF product, was marketed in Japan in 2001 and has been used in wound healing applications in Japan (decubitus and skin ulcer). The usual regimen includes daily dosing for 4 weeks with 30µg FGF2/6 cm² skin area and exhibits only limited efficacy.

Treatment with DNA/cDNA encoding for growth factors has previously been assessed for its ability to promote wound healing in animal models. However, the effects that growth factors themselves have shown on improving wound repair have so far been inconsistent. In addition, treatments have required repetitive, high doses of the growth factor DNA to achieve statistically significant effects in animal models tested. This low efficacy is also uncovering an intrinsic problem of DNA based nucleic acid therapy: DNA, in order to induce protein expression, does not only need to cross the cell membrane and induce cytoplasmic protein synthesis (as functional IVT mRNA) but also needs to be transported into the nucleus to achieve gene transcription and subsequent translation. In addition to this inefficient process, development of DNA therapies also suffers from the risk of potential, uncontrolled genomic insertion of the DNA molecules and associated alterations including development of cellular abnormalities, apoptosis, mutational insertions, cancerogenesis etc. The combination of the intrinsic high risk and low efficacy profile precluded successful development into the clinical practice so far.

Along these lines, preclinical tests of cDNAs of FGF7/KGF or FGF2 in treatment of acute wounds have been performed. The different wound types analysed included for example burns, excisional wounds, dermabrasion, elevated skin flaps. These experiments were designed to analyse wound closure as well as wound healing by applying full length FGF7 and FGF2 cDNAs, naked or complexed with liposomal preparations, to porcine and rodent wound models.

Naked cDNA injections of KGF/FGF7 have been performed in wound healing experiments. Marti et al. treated full thickness excisional wounds in BALB-C mice with intradermal injections (i.d.) of 50µg KGF/FGF7 DNA in PBS at two injection sites followed by electroporation (Marti et al., Gene Ther. 11 (2004): 1780-5). Wounds treated with KGF/FGF7 and electroporation were found to have only 38% smaller wound area 12 days after wound-

ing. Notably, treatment with KGF cDNA without electroporation did not show significant improvements in wound healing over the vehicle controls. Similarly, Lin et al. also tested naked KGF DNA and electroporation and similarly found smaller wound area using the same dose (50µg of KGF in PBS at two injection sites) in a rat sepsis model, and also failed to observe significant effects without electroporation (Lin et al., *Wound Repair Regen.* 14 (2006): 618-24).

Topical application of KGF DNA plasmids has been assessed as a potential treatment for freshly iatrogenically wounded, fragile skin in a murine microdermabrasion model. Treated mice repeatedly received a high amount of plasmid DNA (i.e.: 50µg of plasmid DNA topically every 12 hours over a 4-day period) on an area of microdermal abrasion (Dou et al., *Mol Ther.* 22 (2014): 752-61. doi: 10.1038/mt.2014.2). Epithelial thickness in the wounded and transfected areas were significantly increased compared to the control vector group after 48 hours and dermal thickness 120 hours after treatment.

In addition, Jeschke et al. tested a model of acute wound healing using thermal injury by hot water scalding. Here, Sprague-Dawley rats received weekly subcutaneous (s.c.) injections of 2.2µg KGF in liposomes over four weeks or a liposome only control (Jeschke et al., *Gene Ther.* 9 (2002), 1065-74). In this study, only a very modest acceleration in epithelization was observed as well as an increase in expression of other growth factors, including VEGF and IGF-I, compared to the controls. Additional liposomal gene transfer studies by Jeschke et al. using the same thermal injury model and dosing also showed similar results in Sprague-Dawley rats when treated with Insulin-like growth factor (IGF-I) cDNA, and combinations of KGF and IGF cDNA, respectively. However, initial studies by Jeschke et al. did not address the potential effect of the liposomal formulation itself on wound repair in these scalding models. A study by the same group in 2005 found that s.c. injection of different formulations of liposome alone increased the rate of re-epithelization (Jeschke et al., *Gene Ther.* 9 12 (2005), 1718-24). Indeed, weekly s.c. injection of 0.2 mL DOTAP/Chol liposomes at two injection sites accelerated epithelization by up to 200% as well as significantly increasing KGF, vascular endothelial growth factor (VEGF), and insulin-like growth factor bind-

ing protein 3 (IGFBP-3) levels, compared to saline treated controls. This is highly interesting and points towards very limited efficacy of DNA based therapeutics as liposomal KGF and IGF1 DNA application accelerated wound re-epithelization by almost 250% as reported in a previous study. A 2007 study by Pereira et al. using the same dose and schedule as the Jeschke publications also found a $22\% \pm 5\%$ improvement in re-epithelization following treatment with liposomes alone, compared to an only modest increase to $40\% \pm 5\%$ with KGF-I and liposomes (Pereira et al., *J. Surg. Res.* 139 (2007), 222-8).

For FGF2 DNA based therapeutics only very limited experiments have been described so far addressing wound healing. Fujihara et al. (2005) have shown that transfer of 300 μ g bFGF plasmid DNA to dorsal muscles and subsequent electroporation improves survival of ischemic skin flaps following flap elevation two days after electroporation mainly by inducing angiogenesis from muscle to overlying skin (Fujihara et al., *Br. J. Plast. Surg.* 58 (2005) 511-7). No clear effect on skin architecture has been analysed. Similarly, Ferraro et al. (2010) showed that intradermal injection of plasmid DNA encoding FGF-2 (pFGF) followed by non-invasive cutaneous electroporation could increase blood flow and angiogenesis in a rat model of hindlimb ischemia (Ferraro et al., *Gene Ther.* 17 (2010), 763-9. doi: 10.1038/gt.2010.43). Delivery of pFGF plus electroporation significantly increased FGF-2 expression for 10 days whereas delivery of pFGF without electroporation did not lead to overt improvement. Thus, the main effect associated with cutaneous overexpression of FGF2 has been angiogenesis rather than overt changes in skin architecture other than neoangiogenesis.

Yang et al. (2012) (*Mol. Pharm.* 9 (2012), 48-58. doi: 10.1021/mp200246b) were applying a full length FGF2 construct (6777 bp), encoding a fusion protein of recombinant murine bFGF and enhanced green fluorescent protein (bFGF/eGFP) within a cytomegalovirus promoter expression vector (C-terminal eGFP-tagged protein). In this study, diabetic rats carrying full thickness excisional wounds were treated with fibrous mats covering the wound area and containing FGF2 plasmid PEI polyplexes as component of the fibres, mats soaked in FGF2 plasmid PEI polyplexes, with fibrous mats alone or were left untreated. Wound closure studies showed that the FGF2 receiving groups developed higher

healing rates as compared to non FGF2 treated groups. These effects, although statistically significant, however were modest: control animals showed a wound closure of 67% after 3 weeks when left untreated, whereas fibrous mats were increasing this rate to 78%. Loading of FGF2 plasmid on such mats was leading to an increase to 87%, and integration of the plasmid into the fibers upon production was leading to almost complete wound closure at this time point.

As already summarised above, the success rates of recombinant protein and DNA based therapies in wound healing were very low so far. Moreover, there was a lack of strategies for treatment of hypotrophic skin and atrophic scars which warrants the development of novel treatment paradigms to meet the medical need in the treatment of hypotrophic skin and atrophic scars.

The mRNA used in the present invention contains (at least) five essential elements which are all known and available to a person skilled in the art (in this order from 5' to 3'): a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region for FGF2 or FGF7, a 3' untranslated region (3'-UTR) and a polyadenosine tail (poly-A tail). The coding region should, of course encode a (human) FGF2 or FGF7, the other components may be the (native) FGF2 or FGF7 UTRs or, preferably, other UTRs. Specifically preferred UTRs according to the present invention are UTRs which improve the properties of the mRNA molecule according to the present invention, i.e. by effecting better and/or longer and/or more effective translation of the mRNA into FGF2 and/or FGF7 protein at the site of administration.

A "CAP region" ("5'CAP") refers to a structure found on the 5' end of an mRNA molecule and generally consists of a guanosine nucleotide connected to the mRNA via an unusual 5' to 5' triphosphate linkage. This guanosine nucleotide is methylated on the 7-position directly after capping in vivo by a methyl transferase ("7-methylguanylate cap" ("m7G"), "cap-0"). Further modifications include the possible methylation of the 2' hydroxy-groups of the first two ribose sugars of the 5' end of the mRNA (i.e. "CAP1" and "CAP2"): "CAP1" has a methylated 2'-hydroxy group on the first ribose sugar, while "CAP2" has methylated 2'-hydroxy groups on the first two ribose sugars. The 5' cap is chemically similar to the 3' end of an RNA molecule (the 5' carbon of the cap ribose is bonded, and the 3' unbonded). This pro-

vides significant resistance to 5' exonucleases and is therefore also providing stability in vivo. For generation of mRNAs according to the present invention also CAP analogues may be used including: monomethylated CAP analogue (mCAP), Anti-Reverse Cap Analog (ARCA CAP), m7G(5')ppp(5')A RNA CAP structure analog, G(5')ppp(5')A RNA CAP structure analog, and G(5')ppp(5')G RNA CAP structure analog.

The term "(5'- or 3'-) UTR" refers to the well-established concept of untranslated region of a mRNA in molecular genetics. There is one UTR on each side of a coding sequence on a strand of mRNA. The UTR on the 5' side, is the 5'-UTR (or leader sequence), the UTR on the 3' side, is the 3'-UTR (or trailer sequence). The 5'-UTR is upstream from the coding sequence. Within the 5'-UTR is a sequence that is recognized by the ribosome which allows the ribosome to bind and initiate translation. The mechanism of translation initiation differs in prokaryotes and eukaryotes. The 3'-UTR is found immediately following the translation stop codon. The 3'-UTR plays a critical role in translation termination as well as post-transcriptional gene expression. The UTRs as used in the present invention are usually delivering beneficial stability and expression (translation) properties to the mRNA molecules according to the present invention. The 3' end of the 3'-UTR also contains a tract of multiple adenosine monophosphates important for the nuclear export, translation, and stability of mRNA. This so-called poly-Adenosine (poly-A) tail consists of at least 60 adenosine monophosphates, preferably 100 and most preferably 120 adenosine monophosphates.

The "poly-A tail" consists of multiple adenosine monophosphates; it is a part of naturally occurring mRNA that has only adenine bases. This process called "polyadenylation" is part of the process that produces mature messenger RNA (mRNA) for translation in the course of gene expression. The natural process of polyadenylation begins as the transcription of a gene terminates. The 3'-most segment of the newly made pre-mRNA is first cleaved off by a set of proteins; these proteins then synthesize the poly(A) tail at the RNA's 3' end. In some genes, these proteins add a poly(A) tail at one of several possible sites. Therefore, polyadenylation can produce more than one transcript from a single gene (alternative polyadenylation), similar to alternative splicing. The poly(A) tail is important for the nucle-

ar export, translation, and stability of mRNA. For the present invention, it is therefore mainly the translation and stability properties that are important for a sufficient polyadenylation of the mRNA molecules according to the present invention. During the protein generation, the tail is shortened over time, and, when it is short enough, the mRNA is enzymatically degraded. The poly-A tail according to the present invention is provided in the manner currently used and applied in the art of administering mRNA molecules in human therapy. For example, the poly-A tail may be at least 60 adenosine monophosphates long. According to a preferred embodiment, the poly-A tail is at least 100 adenosine monophosphates long, especially at least 120 adenosine monophosphates. This allows excellent stability and protein generation; however, as for the other features, the action and activity of the mRNA molecule according to the present invention can also be regulated by the poly-A tail feature.

The sequences used in the mRNA molecules according to the present invention can either be native or not. This holds true for the FGF2 or FGF7 coding region as well as for the UTRs.

The term "native" relates to the human FGF2 and FGF7 mRNA in its natural environment.

Preferably, the sequences are not native but are improved to increase various parameters of the mRNA molecule, such as efficacy, stability, deliverability, producibility, translation initiation and translation.

For example, instead of using the native FGF2 and/or FGF7 coding sequence, sequences optimised with respect to GC-content or codon usage (determined by the codon adaption index, CAI) may be used according to preferred embodiments of the present invention (see below).

Particularly preferred sequences disclosed in this invention are improved with respect to UTR compositions and or GC-content and optimised codon usage (determined by the codon adaption index, CAI, i.e. are showing GC contents and CAI above threshold defined in this invention) and are able to increase various parameters including absolute FGF protein production, longevity of FGF expression and especially also efficacy of extracellular matrix production and increase in dermal volume. This is also further illustrated in the examples provided in this invention, e.g.: example 17. Hence, these modified sequences are particu-

larly well suited to achieve a sustainable improvement in hypotrophic skin conditions, especially atrophic scars according to the teachings of this invention.

Particularly preferred sequences according to this invention are containing coding sequences as described in this invention coding for human FGF2 and human FGF7 protein, respectively. Preferred coding sequences for FGF 2 for example comprise SeqID NO:2, SeqID NO:3, SeqID NO:4 for FGF7 and SeqID NO:19, SeqID NO:20 and SeqID NO:21 for FGF2.

The present invention, due to its mechanism, targets treatment of hypotrophic skin conditions, especially atrophic skin conditions, in general; atrophic scars and glucocorticoid (GC)-induced skin atrophy are, however, preferred therapeutic indications addressed with the present invention; whereas cosmetic treatment of the skin is - alternatively - also possible, especially for ageing skin. Atrophic scars are broadly described as exhibiting generalized cutaneous atrophy resulting in loss of cutaneous cells in the epidermis although appear clinically as a loss of normal dermis. Clinically, atrophic scars classically appear as depressions of the skin and commonly occur post acne amongst other causes. The present invention allows administration of a powerful molecule (FGF2 and/or FGF7 encoding mRNA) in a very diligent manner so as to obtain a successful clinical outcome for the patients and at least a significant amelioration of skin condition, especially for atrophic skin tissue. Amelioration of local skin hypotrophy conditions, especially atrophic skin conditions, such as atrophic scars, is measured by quantifying the size of the lesion(s). Invasive measures include the quantification of extracellular matrix components such as collagen, elastin or glycosaminoglykanes based on histological, immunohistochemical or biochemical methods. Evaluations are done at baseline and at defined time points after the treatment. Change is expressed as change from baseline.

According to a preferred embodiment, the present invention therefore preferably addresses the local skin hypotrophy conditions (i.e. the skin diseases resulting in a hypotrophic state of one or several skin layers) selected from the group consisting of cutis laxa, acrodermatitis chronica atrophicans, atrophoderma idiopathica et progressiva Pasini Pierini, scars resulting from perforating dermatoses, atrophy blanche, necrobiosis

lipoidica, radiation dermatitis (skin changes resulting from exposure to ionizing radiation), striae cutis distensae (caused by pregnancy, rapid growth, alimentary obesity), atrophic skin conditions, atrophic scars, glucocorticoid (GC)-induced skin atrophy, and skin ulcer.

As already mentioned, the spectrum addressable by the present invention extends from small reductions in the volume of given skin layers to a complete tissue loss, its maximal variant. With respect to the ulcer indications to be treated according to the present invention, there are numerous causes, including trauma, autoimmunological pathology, reduced perfusion (arterial or venous), psychogenic injury (self-trauma), infections. Specific diseases include ulcerative dermatitis as a result of bacterial infection, ulcerative sarcoidosis, ulcerative lichen planus, diabetic foot ulcer, ulcer associated with high blood pressure, ulcer associated with venous insufficiency, neuropathic ulcer, pressure sore, vasculitis (small and medium size vessels), pyoderma gangraenosum, rheumatoid ulceration, necrobiosis lipoidica, drug-induced necrosis (e.g. caused by warfarin, heparin), ulcers in the context of coagulopathies (e.g. caused by antiphospholipid syndrome, protein S deficiency).

Atrophic scars manifest primarily on the face, chest and back of patients. It most commonly results from acne and chickenpox, but also from surgery, infections, drugs (e.g. steroid injection, penicillamine), autoimmunological processes (e.g. chronic discoid lupus erythematosus), trauma, nerve- and psychogenic (e.g. acne excoriée de jeunes filles) injuries. Hypotrophic/atrophic areas do not constitute an acute/active wound or active site of tissue remodeling but constitute an end-result of inefficient and aberrant repair mechanisms following a local tissue insult. In case of atrophic scars, the decreased dermal volume results in a downward pull of the affected skin area causing a sunken appearance.

Since the major treatment area of the present invention is human medicine, the most preferred embodiment is, of course, a mRNA wherein the coding region encodes human FGF, especially human FGF2 or human FGF7 (as encoded by the various SEQ ID NOs disclosed in the example section of the present invention). These molecules are also preferred for human cosmetic use according to the present invention.

According to a preferred embodiment of the present invention, the present mRNA comprises in the 5'-UTR and/or 3'-UTR (preferably in the 3'UTR) one or more stabilization sequences that are capable of increasing the half-life of the mRNA intracellularly. These stabilization sequences may exhibit a 100% sequence homology with naturally occurring sequences that are present in viruses, bacteria and eukaryotic cells, but may however also be partly or completely synthetic. Examples for such stabilizing sequences are described in: Nucleic Acids Res. 2010; 38 (Database issue): D75-D80. UTRdb and UTRsite (RELEASE 2010): a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs and under <http://utrdb.ba.itb.cnr.it/>.

As a further example of stabilizing sequences that may be used in the present invention, the non-translated sequences (UTR) of the β -globin gene, for example of Homo sapiens or Xenopus laevis, may be mentioned.

Another example of a stabilization sequence has been described in Holcik et al. (Proc. Natl. Acad. Sci. USA 1997, 94: 2410 to 2414) and has the general formula:

(C/U)CCAN_xCCC(U/A)Py_xUC(C/U)CC (SEQ ID NO:38),

which is contained in the 3'UTR of the very stable mRNAs that code for example for alpha(1)-collagen or for alpha globin, and ALOX15 or for tyrosine hydroxylase (and wherein "x" is (independently in N_x and Py_x) an integer of 0 to 10, preferably of 0 to 5 (Holcik et al., 1997), especially 0, 1, 2, 4 and/or 5).

Such stabilization sequences may be used individually or in combination with one another for stabilizing the inventive mRNA as well as in combination with other stabilization sequences known to the person skilled in the art. E.g.: The stabilizing effect of human β -globin 3'-UTR sequences is further augmented by using two human β -globin 3'-UTRs arranged in a head-to-tail orientation.

Accordingly, a preferred embodiment of the FGF2 or FGF7 mRNA according to the present invention is an mRNA molecule, wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR are different from the native FGF2 or FGF7 mRNA, preferably wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR contain at least one stabilization sequence, preferably a stabilization sequence with the general formula (C/U)CCAN_xCCC(U/A)Py_xUC(C/U)CC (SEQ ID

NO:38).

Preferably, the 5'-UTR and/or 3'-UTR are the 5'-UTR and/or 3'-UTR of a different human mRNA than FGF2 or FGF7, preferably selected from alpha Globin, beta Globin, Albumin, Lipoxygenase, ALOX15, alpha(1) Collagen, Tyrosine Hydroxylase, ribosomal protein 32L, eukaryotic elongation factor 1a (EEF1A1), 5'-UTR element present in orthopoxvirus, and mixtures thereof, especially selected from alpha Globin, beta Globin, alpha(1) Collagen, and mixtures thereof.

Accordingly, the present invention preferably relates to an mRNA which comprises in the 3'-UTR one or more stabilization sequences that are capable of increasing the half-life of the mRNA in the cytosol. These stabilization sequences may exhibit a 100% sequence homology with naturally occurring sequences that are present in viruses, bacteria and eukaryotic cells, but may, however, also be partly or completely synthetic. As an example of stabilizing sequences that may be used in the present invention, the non-translated sequences (UTR) of the β -globin gene, for example of homo sapiens or xenopus laevis, may be mentioned. As already stated, another example of a stabilization sequence has the general formula (C/U)CCAN_xCCC(U/A)Py_xUC(C/U)CC, which is contained in the 3'-UTR of the very stable mRNA that codes for alpha-globin, alpha-(1)-collagen, 15-lipoxygenase or for tyrosine hydroxylase (c.f. Holcik et al., Proc. Natl. Acad. Sci. USA 1997, 94: 2410 to 2414). Such stabilization sequences may be used individually or in combination with one another for stabilizing the inventive modified mRNA as well as in combination with other stabilization sequences known to the person skilled in the art.

Another preferred embodiment of the present invention is the 5'-TOP-UTR derived from the ribosomal protein 32L, followed by a stabilizing sequence derived from the albumin-3'-UTR.

Accordingly, a preferred embodiment of the FGF2 or FGF7 mRNA according to the present invention is an mRNA molecule containing a tract of multiple adenosine monophosphates at the 3' end of the 3'-UTR. This so-called poly-adenosine (poly-A) tail consists of at least 60 adenosine monophosphates, preferably at least 100 and most preferably at least 120 adenosine monophosphates.

In certain cases, destabilizing the mRNA might be desirable

as well to limit the duration of protein production. This effect can be achieved by incorporating destabilizing sequence elements (DSE) like AU-rich elements into 3'-UTRs, thus ensuring rapid mRNA degradation and a short duration of protein expression.

Although it may be desired for certain embodiments to provide an mRNA which is devoid of destabilizing sequence elements (DSE) in the 3' and/or 5' UTR, there may be other embodiments, wherein the presence or introduction of such DSEs is advantageous. In general, a "DSE" refers to a sequence, which reduces the half-life of a transcript, e.g. the half-life of the mRNA according to the present invention inside a cell and/or organism, e.g. a human patient. Accordingly, a DSE comprises a sequence of nucleotides, which reduces the intracellular half-life of an RNA transcript.

DSE sequences are found in short-lived mRNAs such as, for example: c-fos, c-jun, c-myc, GM-CSF, IL-3, TNF-alpha, IL-2, IL-6, IL-8, IL-10, Urokinase, bcl-2, SGL T1 (Na(+)-coupled glucose transporter), Cox-2 (cyclooxygenase 2), PAI-2 (plasminogen activator inhibitor type 2), beta(1)-adrenergic receptor or GAP43 (5'-UTR and 3'-UTR).

Further DSEs are AU-rich elements (AREs) and/or U-rich elements (UREs), including single, tandem or multiple or overlapping copies of the nonamer UUAUUUA(U/A)(U/A) (where U/A is either an A or a U) and/or the pentamer AUUUA and/or the tetramer AUUU. Further DSEs are described in Nucleic Acids Res. 2010; 38 (Database issue): D75-D80. UTRdb and UTRsite (RELEASE 2010): a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs and under <http://utrdb.ba.itb.cnr.it/>.

Accordingly, it may also be preferred if the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR contain at least one destabilization sequence element (DSE), preferably AU-rich elements (AREs) and/or U-rich elements (UREs), especially a single, tandem or multiple or overlapping copies of the nonamer UUAUUUA(U/A)(U/A), such as the pentamer AUUUA and/or the tetramer AUUU (the term "U/A" meaning either A or U).

These stabilizing and destabilizing elements can be used alone or in combination to aim at a given duration of protein production and to individualize the treatment of the present invention to the local skin hypotrophy conditions, especially

atrophic skin condition, the severity of affected skin and/or the specific group of patients.

Although also nucleic acids encoding FGFs have been suggested for therapeutic applications, these proposals have either been suggested considerable time ago, were mostly related to DNA (not RNA or specifically mRNA) and were related to completely different fields and modes of administration. Moreover, the advantages revealed in the context of the present invention were not observed for these prior art uses of FGF2-/FGF7-mRNA.

The use of immunostimulatory compositions comprising adjuvant mRNA complexed with a cationic or polycationic compound in combination with free mRNA encoding a tumor antigen has previously been described in WO 2010/037408 A1 for prophylaxis, treatment and/or amelioration of tumor diseases, autoimmune, infectious and allergic diseases. This approach allows efficient translation of the administered free mRNA into the protein of interest, while the mRNA complexed with the adjuvant component induces an immune response. Another approach to stabilize nucleic acid for in vivo application is the modification of nucleic acid sequence such as the addition of a Kunitz domain, a protease inhibitor (WO 2009/030464 A2).

RNA-based therapies for the treatment of rare dermatological diseases and treatments for use in medical dermatology and aesthetic medicine have been suggested: WO 2015/117021 A1 discloses the use of a pharmaceutical composition comprising an RNA composed of one or more non-canonical nucleotides for the treatment of AK, whereby the nucleic acid encodes either for a protein of interest of the group of skin-specific structural or growth factor proteins, or for gene-editing protein targets. Similar, WO 2016/131052 A1 discusses the administration of synthetic RNA comprising canonical and non-canonical nucleotides encoding collagenase as anti-scarring treatment. In both patent applications, the administration of the pharmaceutical composition comprising the synthetic RNA can occur on multiple ways such as subcutaneous, intradermal, subdermal or intramuscular injection, as well as topical.

However, it could be shown with the present invention that a combination of modified and non-modified nucleotides is not better than an unmodified mRNA (more to the contrary, an unexpectedly high reduction by a factor of 10 lower was observed, e.g.

with a FGF7 mRNA containing 5meC and pseudo-U instead of C and U). This result according to the present invention stands also in contrast with other reports wherein the use of non-canonical nucleotides was reported to be advantageous (see e.g. Thess et al., *Molecular Therapy* 23 (2015), 1456-1464; Kariko et al., *Molecular Therapy* 20 (2012), 948-953; Kormann et al. *Nature Biotechnology* 29 (2011), 154-157). In fact, it can be shown with the present invention that the use of exclusively native sequences in the coding region/sequence (CDS) is more effective and that this effect can further be multiplied with the amendments in the CDS. Moreover, also the implied longevity (to avoid substantial cellular toxicity) is better.

In addition, according to certain preferred embodiments, the FGF mRNAs according to the present invention are free of non-canonical nucleotides, and contain a modified UTR and an optimized CDS. Such preferred FGF mRNAs have a further surprising effect in that many more efficient and surprising effects after 24h-120h post transfection are obtained. This is counter-intuitive, and non-expected if native mRNA (coding region) or the recombinant protein is the model for state of the art understanding of FGF function.

EP 2 641 614 A1 discloses a microneedle assembly formulation for prevention or treatment of skin aging or skin scars (UV-damaged skin, hypertrophic scar, atrophic scar, keloids, acne scar, hair loss, suture wound, burn wound, ulcer, bedsore, diabetic ulcer or a disease requiring angiogenesis) comprising a substance consisting e.g. of basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF or FGF1), or a nucleic acid and a plasmid encoding the gene thereof. Regarding proteins, it turned out that clearance of secreted (recombinant) FGFs is extremely fast and that therefore single bolus injections are not guaranteeing successful application for the intended therapeutic use. Usually proteins need to be applied frequently (at least daily) and doses will have to be comparably high as compared to production as triggered by the mRNAs suggested (low ng vs µg).

According to a preferred embodiment, the FGF2 mRNA according to the present invention is not encoding full length FGF2 cDNA but the ORF encoding a short frame, secreted (Fibroblast growth factor 2 (FGF2), a prototypic member of the FGF family, is en-

coded by a single gene.

As already referred to above, alternative translation-initiation codons produce various isoforms: low molecular weight FGF2 (Lo FGF2) is an 18 kDa protein translated from a conventional AUG start codon and its 155 amino acid sequence is common to all FGF2 isoforms. The RNA sequence in the CDS is 468 nucleotides and is an integral part of the naturally occurring full length mRNA sequence as disclosed in a publicly available database (<https://www.ncbi.nlm.nih.gov/nucore>) with the accession numbers: J04513.1 (for all database references herein, a date of 31 July 2017 applies). Alternatively, the sequence is also disclosed in NM_002006.4 and M27968.1, respectively. The high molecular weight (Hi FGF2) isoforms (20.5 and 21 kDa) are produced by starting translation at CUG sites upstream and inframe of the AUG codon. The 21.5kd form has 591 nucleotides in the CDS and encodes 196aa and the CDS of the 22kd form has 633 nucleotides encoding for 210aa. Usage of these CDS variants would also lead to secretion of the short form of FGF2 described in this invention.

Alternative sequences for FGF2 which have been proposed for use also include changes of the CDS: FGF2 is lacking a standard secretion signal and export is mediated by an energy-dependent, non-ER/Golgi pathway. Hence, adding of alternative secretion signals within the FGF2 coding sequence have been suggested to increase secretion and are included: Sohn et al. (2001) use a classical secretion signal sequence of FGF-4, Sasada et al., 1991 use the secretion signal sequence of IL-2, Blam et al. (1988) use the secretion signal sequence of Growth hormone; In addition also mutation of the second and third of the four cysteines (i.e., cys-70 and cys-88) to serine and asparagine have been suggested to increase protein stability without affecting the biological activity of FGF2. Accordingly, also a combination of mutations with altered secretion sequences as mentioned above has been suggested as well. Along these lines: Chen et al 2007 (and references therein) suggest the use of BMP-, specifically BMP-2/4 hybrid secretion signal sequences along with mutation of the second and third of the four cysteines (i.e., cys-70 and cys-88) to serine and asparagine to increase stability and secretion of the mutated FGF2 protein.

The other isoforms and frames in the gene are not preferred

embodiments of the present invention; hence it is usually only a portion of the FGF2 gene which is used according to the present invention, not the full-length form as implied by the EP 2 641 614 A1. A person skilled in the art would - according to the teachings of EP 2 641 614 A1 - thus rather think that a full gene cDNA would lead to in situ production of different forms of FGF2 protein (Hi and Low MW forms) with distinct functions and would not lead to a comparable biological outcome as sole production of a secreted short form. DNA/plasmid also would not have the same expression kinetics and would pose the risk of integration into the genome, hence constitute a potential problem for safety. RNA mediated gene transfer is desirable especially in local applications as it avoids promoter expression uncertainty (expression plasmids, cDNA based approaches relying on external promoters), and provides a defined period for a potent biologic effect for without concerns of long-term deleterious effects. With the RNA delivery approach, target cells serve as a bioreactor for protein synthesis eliminating protein processing and modification difficulties noted with exogenously produced, recombinant products. The mRNA delivery technique allows the use of more potent cellular factors or stimulants than previously possible as it is not associated with long term mutagenic concerns and will be self-limiting due to decline after short period.

WO 2014/089486 A1 discloses compositions comprising at least one mRNA encoding a polypeptide of interest (e.g. FGF2 or FGF7) and a transfer vehicle comprising a lipid nanoparticle or a lipidoid nanoparticle for treating diseases associated with protein or enzyme deficiencies; however, this document does not mention skin diseases such as chronic wounds, ulcers etc. US 2007/149475 A1 discloses a method of augmenting transient protein synthesis in a cell for improving wound healing by delivering eIF-4E mRNA alone or in combination with mRNAs encoding e.g. growth factors necessary for wound healing such as FGF-2. WO 2010/037408 A1 describes an immunostimulatory composition comprising a) an adjuvant component comprising of at least one complexed mRNA e.g. FGF2 or bFGF and b) at least one free mRNA for treating e.g. skin diseases. This approach is counterintuitive to the approach according to the present invention: According to the present invention, immunostimulatory events should be kept as low as pos-

sible or be avoided completely. The approach taught in WO 2010/037408 A1 is to eliminate endogenous proteins like FGFs by inducing an immune response against them. Accordingly, the use of KGF/FGF7 and FGF2 as therapeutic components to treat e.g. scars is not within the teaching of this document but to use the factors to create a response against them. The therapeutic principle in WO 2010/037408 A1 is thus elimination of the endogenous KGF/FGF7 and FGF2 protein(s) for treatment rather than use of the proteins as therapeutic agents (as in the present invention).

Moreover, preferred embodiments of the present invention are using improved UTRs and improved mRNA coding sequences (with regard to codon uses).

It is therefore evident that growth factors, such as FGFs, especially FGF2 and FGF7, have not been suggested to be applied in the context of the present invention.

General concepts for improved mRNA-based therapeutics (see e.g. Sahin et al., Nat. Rev. Drug Disc. 2014. 13(10): 759-780) are also applicable for the present invention.

Although in most cases, the use of exclusively canonical nucleotides, there may be certain occasions where the FGF2 and FGF7 mRNA according to the present invention may contain other monophosphate nucleosides than those of cytidine (C), uridine (U), adenosine (A) or guanosine (G) residues (the canonical nucleotides). There are a significant number of naturally occurring analogs of these monophosphate nucleosides and also (even more) synthetic variants of these mRNA residues. Embodiments of such variants can be found e.g. in WO 2014/153052 A2.

According to an embodiment, in the present FGF mRNA, at least 5%, preferably at least 10%, more preferably at least 30%, especially at least 50% of all

- cytidine residues are replaced by 5-methyl-cytidine residues, and/or
- cytidine residues are replaced by 2-amino-2-deoxy-cytidine residues, and/or
- cytidine residues are replaced by 2-fluoro-2-deoxy-cytidine residues, and/or
- cytidine residues are replaced by 2-thio-cytidine residues, and/or
- cytidine residues are replaced by 5-iodo-cytidine residues,

- and/or
- uridine residues are replaced by pseudo-uridine residues, and/or
 - uridine residues are replaced by 1-methyl-pseudo-uridine residues, and/or
 - uridine residues are replaced by 2-thio-uridine residues, and/or
 - uridine residues are replaced by 5-methyl-uridine residues, and/or
 - adenosine residues are replaced by N6-methyl-adenosine residues.

Specific embodiments are FGF2 and FGF7 mRNAs, wherein in the FGF mRNA, at least 5%, preferably at least 10%, more preferably at least 30%, especially at least 50% of all

- cytidine residues are replaced by 5-methyl-cytidine residues, and/or
- uridine residues are replaced by pseudo-uridine residues, and/or
- uridine residues are replaced by 2-thio-uridine residues.

In the course of the present invention it has been surprisingly found out that even more improved results can be obtained if the GC-content (or GC to AU ratio) of the mRNA is further increased. The reason why this was specifically surprising was because the native FGF2 and FGF7 sequences were already regarded as being optimal with respect to translation/expression efficiency. However, if the FGF2 mRNA according to the present invention is designed with a GC to AU ratio of at least 51.7% or more preferred at least 52% (e.g. at least 52.1, at least 52.2, at least 52.3), or the FGF7 mRNA according to the present invention is designed with a GC to AU ratio of at least 39.5% or more preferred at least 43%, the performance according to the present invention further increases. Accordingly, the GC to AU ratio is preferably of at least 51.7%, preferably of at least 52%, more preferred 55%, even more preferred at least 58%, especially at least 60% in case of the FGF2 mRNA and at least 39,5%, preferably of at least 43%, more preferred 45%, even more preferred at least 50%, especially at least 55% in case of the FGF7 mRNA.

In connection with the nucleoside variants disclosed above, it is important to note that the specific preferred variants described above do not influence the GC content, i.e. the variant

is conservative in this respect (e.g. a cytidine variant still counts as a cytidine for the calculation of the GC content).

Another surprising observation revealed in the course of the present invention was the fact that FGF2/FGF7-mRNAs with increased Codon Adaptation Index (CAI) also showed improved performance in the present invention, especially with respect to expression capacity within the cell.

The CAI is a measurement of the relative adaptiveness of the codon usage of a gene towards the codon usage of highly expressed genes. The relative adaptiveness (w) of each codon is the ratio of the usage of each codon, to that of the most abundant codon for the same amino acid. The CAI index is defined as the geometric mean of these relative adaptiveness values. Non-synonymous codons and termination codons (dependent on genetic code) are excluded. CAI values range from 0 to 1, with higher values indicating a higher proportion of the most abundant codons (Sharp et al., *Nucleic Acids Res.* 15 (1987): 1281-1295., Jansen et al., *Nucleic Acids Res.* 31 (2003): 2242-2251).

Therefore, a preferred embodiment of the present invention relates to an FGF2 and FGF7 mRNA, wherein the FGF2 mRNA has a codon adaptation index (CAI) of at least 0.76, preferably at least 0.77, at least 0.8, at least 0.82, at least 0.83, at least 0.84, at least 0.85, at least 0.86, at least 0.87, at least 0.88, at least 0.89 and, wherein the FGF7 mRNA has a codon adaptation index (CAI) of at least 0.71, at least 0.74, preferably at least 0.75, at least 0.76, at least 0.77, at least 0.78, at least 0.79, at least 0.8, at least 0.81, at least 0.82, at least 0.83, at least 0.84, at least 0.85. Even a more preferred CAI of the FGF2 mRNAs according to the present invention is at least 0.9, especially at least 0.91. Even a more preferred CAI of the FGF7 mRNAs according to the present invention is at least 0.86, especially at least 0.87.

For comparison: native GC to AU ratio of FGF2 is 51.7% and of FGF7 is 39.5%; native CAIs of FGF2 is 0.76 and of FGF7 is 0.74.

Preferred CG to AU ratios are higher than the native ones, e.g. for FGF2 at least 52%, preferably at least 55%, especially at least 60% or for FGF7 at least 40%, preferably at least 45%, especially at least 50%.

Even more preferred, the FGF2 mRNAs according to the present

invention have a CAI of at least 0.76 AND a GC content of at least 51.7% and the FGF7 mRNAs a CAI of at least 0.74 AND a GC content of at least 39.48% (or an even more preferred higher CAI/GC content).

Preferred consensus sequences of the FGF mRNA according to the present invention for FGF7 are SEQ ID NOs:12, 13 and 14; most preferred SEQ ID NO:12.

SEQ ID NO:12 comprises optimized GC-rich sequences; SEQ ID NO:13 comprises all optimized sequences including AU-rich sequences; SEQ ID NO:14 is the consensus for all optimised as well as the native sequence.

Preferred consensus sequences of the FGF mRNA according to the present invention for FGF2 are SEQ ID NOs:30, 31 and 32; most preferred SEQ ID NO:30.

SEQ ID NO:30 comprises optimized GC-rich sequences; SEQ ID NO:31 comprises all optimized sequences including AU-rich sequences; SEQ ID NO:32 is the consensus for all optimised as well as the native sequence.

Accordingly, the coding region of the FGF mRNA encoding human FGF7 is preferably SEQ ID NO:12, especially SEQ ID NOs:2, 3, 5, 6, 7, 8, 9, 10, or 11; the coding region of the FGF mRNA encoding human FGF2 is preferably SEQ ID NO:30, especially SEQ ID NOs:19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29.

As shown in the example section, transfection of fibroblasts with the optimized FGF mRNA variants provided with the present invention differs in terms of its overall kinetics from what is known in the field about other mRNAs. Upon delivery of mRNA into a given cell, which is typically achieved quickly when supported by appropriate transfection agents, the mRNA content within a given cell is constantly dropping. In this regard, IVT mRNA is usually behaving as intrinsic mRNA as it is degraded by the same cellular processes. The amount of protein produced upon delivery parallels the amount of the respective IVT mRNA within the cell with a certain delay, which basically reflects the time needed to activate the translation machinery. Typically, after an initial peak, the level of the protein produced in cells upon transfection with IVT mRNA is constantly falling.

Surprisingly, and in sharp contrast to the usual situation described above, delivery of FGF mRNA variants into cells is characterized by a dissociation between the mRNA and protein ki-

netics. While the IVT mRNA is being gradually degraded upon delivery, protein secretion as shown here begins to rise on the first day (i.e. expression is lowest for the first 24h). It reaches a plateau on the second day, which is sustained for several days before FGF production is waning.

As shown in the example section, this pattern was obtained with 3 different cell lines of two origins from three species (mouse: 3T3 (fibroblast), pig: keratinocytes (in epithelial sheets), human: BJ cells (fibroblasts)). This is consistent with an effect of IVT mRNA-induced FGF protein on the auto- or paracrine regulation of endogenous FGF production.

Interestingly, this pattern is not achieved upon addition of recombinant FGF protein at similar amounts as expressed at 24h post transfection to the cells/organs. There, no such autoregulation has been observed 24h post addition of recombinant FGF protein suggesting that mRNA-induced expression is able to activate different intra- and extracellular effects compared to mere protein substitution.

The optimized sequences according to the present invention therefore have i.a. a very surprising effect compared to the native sequences: with the optimized sequences of FGF2 and FGF7, a significant prolongation of the effect can be obtained. Whereas it may be expectable that a peak of activity can be achieved 24 h after transformation, this is significantly different with the optimized sequences according to the present invention. As also disclosed in the example section of the present invention, the activity of the native and the optimized sequences is comparable in the initial phase after transformation. However, this changes significantly in the further course: Whereas the native sequence does not produce significant activity after 120 h anymore, the optimized sequences as provided with the present invention produce a 10-fold and an almost 100-fold improved effect. Moreover, it has to be emphasized that this effect after 120 h is even higher than after 24 h. It follows that administration of the mRNAs according to the present invention to human patients changes treatment paradigms by both significantly reducing the application frequency as compared to other, currently described approaches, as well as significantly surpassing the efficacy of currently described approaches. Such a treatment means e.g.: weekly application instead of daily injection and achieving in-

creased treatment success in patients using the envisaged mRNAs. This increased success is anticipated to result from the intrinsic differences achieved within the treated area by localized, in situ expression of FGFs by the mRNAs according to the present invention.

According to a preferred embodiment, the FGF2/FGF7 mRNA according to the present invention is administered subcutaneously, intradermally, transdermally, epidermally, or topically, especially epidermally.

Administration of the present FGF2/FGF7 mRNA can be performed according to optimised expression aims, depending on the amount of mRNA applied, the stability of the mRNA molecule and the status of disease. For example, the FGF2/FGF7 mRNA may be administered at least once, at least twice, at least twice within one month, preferably weekly. For example, if the FGF2/FGF7 mRNA may be administered at least twice, at least twice within one month, preferably weekly doses applied may vary.

The amount of mRNA delivered per dose may also be made dependent on the stability of the molecule, etc.. Preferably the FGF2/FGF7 mRNA according to the present invention is administered in an amount of 0.01µg to 100 mg per dose, preferably of 0.1µg to 10mg per dose, especially of 1µg to 1mg per dose.

Suitable formulations for mRNA therapeutics are well available in the art (see e.g. Sahin et al., 2014; WO 2014/153052 A2 (paragraphs 122 to 136), etc.).

The present invention therefore also relates to a pharmaceutical formulation comprising an FGF2/FGF7 mRNA according to the present invention. The present formulation comprises the mRNA in a pharmaceutically acceptable environment, e.g. with suitable components usually provided in mRNA therapeutics (excipients, carriers, buffers, auxiliary substances (e.g. stabilizers), etc.)

The mRNA formulations according to the present invention preferably contain a suitable carrier. Suitable carriers include polymer based carriers, such as cationic polymers including linear and branched PEI and viromers, lipid nanoparticles and liposomes, nanoliposomes, ceramide-containing nanoliposomes, proteoliposomes, cationic amphiphilic lipids e.g: SAINT®-Lipids, both natural and synthetically-derived exosomes, natural, synthetic and semi-synthetic lamellar bodies, nanoparticulates, calcium

phosphor-silicate nanoparticulates, calcium phosphate nanoparticulates, silicon dioxide nanoparticulates, nanocrystalline particulates, semiconductor nanoparticulates, dry powders, poly(D-arginine), nanodendrimers, starch-based delivery systems, micelles, emulsions, sol-gels, niosomes, plasmids, viruses, calcium phosphate nucleotides, aptamers, peptides, peptide conjugates, small-molecule targeted conjugates, polylactic-co-glycolic acid (PLGA) polymers and other vectorial tags. Also contemplated is the use of bionanocapsules and other viral capsid protein assemblies as a suitable carrier. (Hum. Gene Ther. 2008 Sep;19(9):887-95).

Preferred carriers are cationic polymers including linear and branched PEI and viromers, lipid nanoparticles and liposomes, transfersomes, and nanoparticulates including calcium phosphate nanoparticulates (i.e. naked RNA precipitated with CaCl_2 and then administered).

A preferred embodiment of the present invention relates to the use of non-complexed mRNA, i.e. non-complexed mRNA in a suitable aqueous buffer solution, preferably a physiological glucose buffered aqueous solution (physiological). For example, a 1xHEPES buffered solution; a 1xPhosphate buffered solution, Na-Citrate buffered solution; Na-Acetate buffered solution; Ringer's Lactate solution; preferred with Glucose (e.g.: 5% Glucose); physiologic solutions can be preferably applied.

Preferably the present invention applies liposomes, especially liposomes which are based on DOTAP, DOTMA, Dotap-DOPE, DOTAP-DSPE, Dotap-DSPE-PEG, Dotap-DOPE-PEG, Dotap-DSPE-PEG-Na-Cholate, Dotap-DOPE-PEG-Na-Cholate, DOTAP with cationic amphiphilic macromolecules (CAM) as complexes, and combinations thereof.

According to another aspect, the present invention relates to a kit for administering the FGF2/FGF7 mRNA according to the present invention to a patient comprising

- the FGF mRNA as defined herein, and
- a skin delivery device.

Preferably, the skin delivery device is

- an intradermal delivery device, preferably selected from the group consisting of needle based injection systems,
- a transdermal delivery device, preferably selected from the group consisting of transdermal patches, hollow and solid

microneedle systems, microstructured transdermal systems, electrophoresis systems, and iontophoresis systems, or
 - an epidermal delivery device, preferably selected from the group consisting of needle free injection systems, laser based systems, especially Erbium YAG laser systems, and gene gun systems.

These administration devices are in principle available in the art; adaption to the administration of the mRNA according to the present invention is easily possible for a person skilled in the art.

The present invention also relates to a method for treating local skin hypotrophy conditions, preferably atrophic skin conditions, especially atrophic scars and glucocorticoid (GC)-induced skin atrophy, wherein the mRNA according to the present invention is administered in an effective amount to a patient in need thereof.

According to a further aspect, the present invention also relates to the use of the mRNAs according to the present invention for the cosmetic treatment of ageing skin, e.g. UV-damaged skin, hair loss, etc.. Also for these aspects, the molecules, formulations (adapted to cosmetic purposes), and methods disclosed with the present invention are suitable. The present invention therefore also relates to a cosmetic skin care method wherein an FGF mRNA according to the present invention is contacted with the human skin, especially an ageing skin. The present invention also contemplates cosmetic formulations comprising an FGF mRNA according to the present invention and a cosmetic carrier. Cosmetic carriers are well available in the art, often overlapping with the ingredients for a pharmaceutical formulation as disclosed above. Preferably, the cosmetic formulation according to the present invention is provided as an ointment, a gel, especially a hydrogel, an emulsion and/or contains liposomes, cationic polymers, nano- or microparticles.

Sequences:

SEQ ID NO:1 FGF7 native

```

augcacaau   ggauacugac   auggauccug   ccaacuuugc   ucuacagauc
augcuuucac  auuauucuguc  uaguggguac  uauaucuuua  gcuugcaaug  acau-
gacucc  agagcaaauug  gcuacaaaug  ugaacuguuc  cagcccugag  cgacacacaa
gaaguuauga  uuacauggaa   ggaggggga  uaagagugag  aagacucuc
  
```

ugucgaacac agugguaccu gaggaucgau aaaagaggca aaguaaaagg gacccaa-
 gag augaagaaua auuacaauau cauggaaauc aggacagugg caguuggaau ugug-
 gcauc aaaggggugg aaagugaauu cuaucuugca augaacaagg aaggaaaacu
 cuaugcaaag aaagaaugca augaagauug uaacuucaaa gaacuaauuc uggaaaac-
 ca uuacaacaca uaugcaucag cuaaauggac acacaacgga ggggaaaugu
 uuguugccuu aaaucaaaag gggauuccug uaagaggaaa aaaaacgaag aaa-
 gaacaaa aaacagccca cuuucuuccu auggcaauaa cuuaa

SEQ ID NO:2 FGF7 HUMAN MOD

augcacaau ggauucucac auggauucug ccuacguugc ucuacagaag
 cugcuuucac aucaucuguc uugugggac uaucucacug gcuugcaaug acau-
 gacacc ggaacagaug gcaaccaaug ugaacuguuc uccccagaa aggcauacca
 gaagcuacga cuacauggaa ggaggggaua ucagggguucg cagauuguuc ugucgua-
 cuc agugguauuc ucgcaucgac aaacggggua aggugaaggg aacacaggag au-
 gaagaaca acuacaacau cauggagauu cggacaguug cagucggggu ugucgccaau
 aagggugugg aaucggaguu cuaucuggcc augaacaag aaggcaaacu
 guauggcaag aaagagugca augaggauug cauuucaaa gagcugauc uggagaac-
 ca cuacaacacc uaugcuagug cgaauuggac ccuaauugga ggggaaaugu uugug-
 gcacu caucagaag ggcauacccg uacgaggcaa gaaaacgaag aaggagcaaa
 agaccgcuca uuucugccc auggccaauca cuuga

SEQ ID NO:3 FGF7

augcacaagu ggauccugac cuggauccug ccuacacugc uguacagaag
 cugcuuccac aucaucugcc ucgugggac aaucagccug gccugcaacg
 auaugacccc ugagcagaug gccaccaacg ugaacuguag cagccccgag aga-
 cacacc gguccuacga uuauauggaa ggcggcgaca ucagagugcg gcggcuguuc
 uguagaacc agugguauuc gcggauucgac aagcggggca aagugaaggg cacccaa-
 gag augaagaaca acuacaacau cauggaaauc cggaccgugg ccgugggcau cgug-
 gcuaau aagggcgucg agagcgaguu cuaccuggcc augaacaag agggcaagcu
 guacgccaag aaagagugca acgaggacug caacuucaaa gagcugauc ucgagaac-
 ca cuacaauacc uacgccagcg ccaaguggac ccacaauggc ggcgaaaugu ucgug-
 gccu gaaccagaaa ggcauacccg ugcgcggcaa aaagaccaa aaagagcaga
 aaacggcca cuuccugccu auggccaauca cuuaa

SEQ ID NO:4 FGF7

augcacaagu ggauccucac auggauccug ccuacgcugc ucuaccgag
 cugcuuccac aucaucuguc uggugggac uaucucacug gcuugcaacg acau-
 gacccc ggagcagaug gcaaccaacg ugaacuguag cccccagag aggcacacc
 ggagcuacga cuacauggag ggaggggaca ucaggguccg cagacuguuc ugucgua-
 cuc agugguaccu gcgcaucgac aagcggggua aggugaaggg aaccagag au-

gaagaaca acuacaacau cauggagauc cggacagugg cggucgggau cgucgccauc
 aagggugugg aguccgaguu cuaccuggcc augaacaagg agggcaagcu
 guacgccaag aaggagugca acgaggacug caacuucaag gagcugauc uggagaac-
 ca cuacaacacc uacgcuagug cgaaguggac ccacaacgga ggggagaugu ucgug-
 gcacu caaccagaag ggcauccccg uccgaggcaa gaagacgaag aaggagcaga
 agaccgcca cuuccugccc auggccauca ccuga

SEQ ID NO:5 FGF7

augcauagu ggauucuac auggauucuc ccaacacuuc uuuacagauc
 augcuuau auuauuguu uggugggaac gauuucucu gcuuguaaug
 auaugacucc agagcaaau gcuacuaau uuaacuguuc cucaccugag cgucuauc-
 ua gaucuuauga uuacauggag ggaggugaua uaagaguua gagacuuuuc
 ugucgaacac agugguaucu gagaaucgau aagagaggua aagucaaagg aaccag-
 gag augaagaaua acuacaauu cauggagauc aggacagugg caguuggaau
 aguugcauc aaaggagucg aaagugaguu cuaucuugcu augaacaagg
 aaggaaaacu guacgcaaag aaagaugua augaggauug caacuucaag
 gagcuuaucc uggaaaacca uuacaacacc uaugcaagug caaauggac ucacaac-
 gga ggagaaaugu uuguugcauu gaucagaaa gggauaccug ugagaggaaa
 gaaaaccaag aaagaacaga aaacugcuca cuuucuuccu auggcuauua ccuga

SEQ ID NO:6 FGF7

augcacaagu ggauccugac cuggauccug cccaccugc uguacagaag
 cugcuuccac aucaucugcc uggugggac caucagccug gccugcaacg acau-
 gacccc cgagcagaug gccaccaacg ugaacugcag cagccccgag agacacacca
 gaagcuacga cuacauggag ggcggcgaca ucagagugag aagacuguuc ug-
 cagaacc agugguaccu gagaaucgac aagagaggca aggugaagg caccagggag
 augaagaaca acuacaacau cauggagauc agaaccgugg ccgugggcau cgug-
 gccauc aagggcgugg agagcgaguu cuaccuggcc augaacaagg agggcaagcu
 guacgccaag aaggagugca acgaggacug caacuucaag gagcugauc uggagaac-
 ca cuacaacacc uacgccagcg ccaaguggac ccacaacggc ggcgagaugu ucgug-
 gccu gaaccagaag ggcauccccg ugagaggcaa gaagaccaag aaggagcaga
 agaccgcca cuuccugccc auggccauca ccuga

SEQ ID NO:7 FGF7

augcacaagu ggauccugac cuggauccug cccaccugc uguaccgag
 cugcuuccac aucaucugcc uggugggac caucagccug gccugcaacg acau-
 gacccc cgagcagaug gccaccaacg ugaacugcag cagccccgag cgccacacc
 gcagcuacga cuacauggag ggcggcgaca uccgugugcg ccgcuuguuc ugccg-
 cacc agugguaccu ggcgaucgac aagcgcgga aggugaagg caccagggag au-
 gaagaaca acuacaacau cauggagauc cgcaccgugg ccgugggcau cguggccauc

aagggcgugg agagcgaguu cuaccuggcc augaacaagg agggcaagcu
 guacgccaag aaggagugca acgaggacug caacucaag gagcugauc uggagaac-
 ca cuacaacacc uacgccagcg ccaaguggac ccacaacggc ggcgagaugu ucgug-
 gccu gaaccagaag ggcauccccg ugcgcgga gaagaccaag aaggagcaga
 agaccgcca cuuccgccc auggccauca ccuaa

SEQ ID NO:8 FGF7

augcauaagu ggauucuac auggauucuc ccaacacugc uguacagguc
 augcuuucac auuauucugc ugguggaac gauuucucu gcuugcaaug acau-
 gacucc agagcaaaug gcuacuaaug ugaacuguuc cucaccugag cgucuaucua
 gaucuauga cuacauggag ggaggugaua uaagagugag gagacuuuuc
 ugucgaacac agugguaucu gcggaucgau aagagaggua aagucaaagg caccag-
 gag augaagaaua acuacaauau cauggagauc aggacagugg caguuggaau
 aguugcaauc aaaggggucg aaagcgaguu cuaucuugcu augaacaagg
 aaggcaaacu guacgccaag aaagaaugca augaggauug caacucaag
 gagcuuaucc uggaaaacca uuacaacacc uaugcaagug caaauggac ucacaac-
 gga ggggaaaugu uuguugcauu gaucagaaa gggauaccug ugagaggcaa
 gaaaaccaag aaagaacaga aaacugcca cuuucuuccu auggcuauua ccuga

SEQ ID NO:9 FGF7

augcauaagu ggauauugac guggauuuua ccuacucucc uauauagguc
 cugcuuccau auauuuguu uggugggcac cauuucucu gccugcaaug
 auaugacacc cgagcagaug gcaaccaacg uaaacuguuc cucaccggag cgacauac-
 ga gaagcuacga cuacauggag ggaggugaua uuagggucag acgccuguuu ugucg-
 gacac agugguaucu uagaauugac aaacguggua aggucaagg gaccagga au-
 gaaaaaua acuauauau cauggaaauc cgcaccgugg caguggggau cguggcgauc
 aaggagugg aaagcgaau cuaucuggcu augaacaag agggaaagcu guacgcu-
 aaa aaagaaugca augaggacug caacuuaaa gaacugauc ucgagaauca
 cuacaauacc uacgccagug ccaaguggac acacaacggg ggcgagaugu ucguug-
 cacu gaaccagaag ggcaucccag uucggggcaa gaaaacaaaa aaggagcaaa
 agacugcuca cuuucuccg auggccauca cuuga

SEQ ID NO:10 FGF7

augcauaau ggauccuac guggauacug ccgacacucc uuuauagguc
 uuguuuucac auauuugcc ucguuggaac uauaucucu gccugcaacg acau-
 gacccc agaacaaaug gcuacaaacg ugaauuguuc cagucccgaa agacacacgc
 gaaguuuga cuacauggaa ggcggcgaua uaagaguug gagacuuuuu
 ugucgaacgc aaugguaucu gaggauugac aagcgcgga agguaaaagg gaccag-
 gag augaagaaca acuauaacau aauggagauu aggacagugg cugugggcau
 cguagcgauc aaagguguag aaucagaguu uuaccuggcc augaacaag aaggu-

aaacu uuaugcuaaa aaagaaugca acgaagauug uaacuucaaa gaaugaucc
uugaaaauca cuauaacaca uaugcauccg cgaaguggac acauaacggg ggagaaau-
gu ucgucgcuu gaaucacaaa gguauuccgg uucggggaaa aaaaaccaag
aaggagcaga agacggcuca cuucuugcca auggccaaua cuuaa

SEQ ID NO:11 FGF7

augcacaagu ggaucuuac guggauacuc ccaacacuuu uguaucgaag
uuguuuucac auuauuugcc uggucggcac gauuucuuug gccugcaacg
auaugacacc ggaacagaug gcuacaaacg uaaacuguag uucacccgag cgg-
cacacuc gaucuuacga uuacauggaa gguggagaca ucaggguuag aagacucuuu
ugcaggacgc aaugguaccu ccgcauagau aagagaggaa aggugaaagg aacacag-
gaa augaaaaua acuacaacau aauggaaaau cggacugucg cugugggaa
cguugccauc aaaggagugg aaucagaauu cuaccuggcu augaauaagg agggaaa-
gcu cuaugcgaaa aaggagugca acgaggacug uauuuucaaa gaacuuaucc
uugaaaacca uuacaacacc uaugcgagug ccaaguggac ucauaacggg ggugagau-
gu ucguagcucu gaucagaag ggcauuccgg uccggggaaa gaagacuaag aa-
gagcaga aaacggcaca cuuucuuccu auggcgauua cauaa

SEQ ID NO:12 FGF7 consensus (optimized GC-rich sequences)

augcacaaru ggaucyusac muggauycug ccyacvyugc usuacmgmag
cugcuuycac aucaucugyc ubgugggcac haucwsmcug gcyugcaayg ayaugac-
mcc bgarcagaug gmaccaayg ugaacugyws ywscmmgar mgvcayaccm gwsw-
cuacga yuayauggar gmggsgaya ucmgvubmg vmgvyuguuc ugmghacyc
agugguaycu kmgvaucgac aarmgvgya argugaagg macmcargag augaa-
gaaca acuacaacau cauggarauy mgvacmgukg cvgusggsau ygusgcyauh
aaggygusg arwscgaguu cuaycuggcc augaacaarg arggcaarcu
guaygccaag aargagugca aygaggayug caayuucar gagcugauyc usgagaac-
ca cuacaayacc uaygcyagy csaaruggac ccayaayggm ggsgaraugu uygug-
gcmcu saaycagaar ggcaumcccg uvmgmggcaa raaracsar aargagcara
aracsgcbca yuucyugccy auggccauca cyura

SEQ ID NO:13 FGF7 consensus (all optimized sequences)

augcayaaru ggauhyubac vuggauhyuv ccnacnyuby unuaymgvws hug-
yuucyay auhauyugyy ubgubggmac nauhwshyuk gcyugyaayg ayaugachcc
ngarcaraug gchachaayg udaayugyws ywshcchgar mgncayacbm
gvwsyuayga yuayauggar gghggngaya uhmgvgubmg vmgvyubuuy
ugymgnacnc arugguaycu bmgvauhgay aarmnggna arguvaargg vacmcar-
gar augaaraaya acuayaayau mauggarauy mgvachgubg cngubggvau
hgungcnauh aargnguvg arwshgaruu yuaycukgcy augaayaarg argghaar-
cu buaygcnaar aargarugya aygargayug yaayuuyaar garyukauyc ub-

garaayca yuayaayacm uaygcnwsyg cvaaruggac hcayaayggn ggngaraugu
uygungcnyu saaycaraar ggbauhccng unmgvggmaa raaracnaar aargar-
cara aracbcnca yuuyyubccn auggcbauha chura

SEQ ID NO:14 FGF7 consensus (all optimized and native sequences)
augcayaaru ggauhyubac vuggauhyuv ccnacnyuby unuaymgvws hug-
yuuycay auhauyugyy ungubgghac nauhwshyud gcyugyaayg ayaugachcc
ngarcaraug gchachaayg udaayugyws ywshcchgar mgncayacnm
gvwsyuayga yuayauggar gghggngaya uhmgvgubmg vmgvyubuuy
ugymgnacnc arugguaycu bmgvauhgay aarmgngna arguvaargg vacmcar-
gar augaaraaya ayuayaayau mauggarauy mgvachgubg cngubggvau
hgungcnauh aarggnguvg arwshgaruu yuaycukgch augaayaarg argghaar-
cu buaygcnaar aargarugya aygargayug yaayuuyaar garyudauyc ub-
garaayca yuayaayacm uaygcnwsyg cnaaruggac hcayaayggn ggngaraugu
uygungcnyu vaaycaraar ggbauhccng unmgvggmaa raaracnaar aargar-
cara aracbcnca yuuyyubccn auggcnauha chura

SEQ ID NO:15 FGF protein

MHKWILTWIL PTLLYRSCFH IICLVGTISL ACNDMTPEQM ATNVNCSSPE RHTRSVDYME
GGDIRVRRLE CRTQWYLRID KRGKVKGTQE MKNNYNIMEI RTVAVGIVAI KGESEFYLA
MNKEGKLYAK KECNEDCNFK ELILENHNT YASAKWTHNG GEMFVALNOK GIPVRGKTK
KEQKTAHFLP MAIT

SEQ ID NO:16 Model Seq including the 5'UTR (aGlobin, human+
Kozak)

gggagacaua aaccugggcg cgcucgcggc cggcacucu ucuggucucc acagacucag
agagaaccca cc

SEQ ID NO:17 Model Seq including the 3'UTR (aGlobin, human+ Poly
A site and first A (of 120))

gcuggagccu cgguggccau gcuucuugcc ccuugggcu cccccagcc ccuccuccc
uuccugcacc cguacccccg uggucuuuga auaaagucug agugggcggc a

SEQ ID NO:18 FGF2 native

auggcagccg ggagcaucac cacgcugccc gccuugcccg aggauggcgg
cagcggcgcc uucccgcccg gccacucaa ggaccccaag cggcuguacu
gcaaaaacgg gggcuucuuc cugcgcaucc accccgacgg ccgaguugac
gggguccggg agaagagcga ccucacauc aagcuacaac uucaagcaga agagagag-
ga guugugucua ucaaaggagu gugugcuaac cguuaccugg cuaugaagga agaug-
gaaga uuacuggcuu cuaaaugugu uacggaugag uguuucuuuu uugaacgauu

ggaaucuaau aacuacaaua cuuaccgguc aaggaaauac accaguuggu augug-
gcacu gaaacgaacu gggcaguaua aacuuggauc caaaacagga ccugggcaga aa-
gcuaauacu uuuucuucca augucugcua agagcuga

SEQ ID NO:19 FGF2 human mod

auggcugcag gcaguaucac cacucuccca gcauugccug aagauggagg
uucaggcgcc uuuccuccag gccacuuuaa agaccccaag agacuguacu gcaa-
gaaugg uggguucuuc cugcgcauuc aucccgaugg acguguagac ggagucaggg
aaaagucaga uccgcacaua aagcuccagc uccaagcuga ggaaagaggg guugug-
ucca ucaaaggggu gugugccaau cgcuaucugg cgaugaaaga ggacggcaga
cuucuggcua gcaagugugu gacagacgag ugcuuucu uugagcgguu
ggaguccaac aacuacaaca ccuaucgaag caggaaguac acgucuuggu augucg-
cacu gaaacggacu gggcaguaca agcuuggcag caagacagga ccuggucaga aa-
gccauucu guuucugccc augucugcca aaaguuga

SEQ ID NO:20 FGF2

auggccgcug gcucuauuac aacacugccc gcucugccug aggauggcgg aucuggug-
cu uuuccaccug gccacuucaa ggaccccaag cggcuguacu gcaagaacgg cggau-
ucuuc cugcggauuc accccgacgg aagaguggac ggcgugcggg aaaaaagcga
cccucacauc aagcuccagc ugcaggccga agagagaggg gucgucagua
ucaaagggcu gugcgccaac agauaccugg ccaugaagga agauggccgg
cugcuggccu cuaagugcgu gaccgaugag ugcuuucu ucgaacggcu ggaaa-
gcaac aacuacaaca ccuacagaag ccggaaguac accucuuggu acguggcccu
gaagcggacc ggccaguaua agcugggcuc uaagacaggg ccaggccaga ag-
gccauccu guuucugccu augagcgcca agagcuga

SEQ ID NO:21 FGF2

auggcugcag gcagcaucac caccuuccca gcacugccug aggacggagg
uuccggcgcc uuuccuccag gccacuucaa ggaccccaag cgccuguacu gcaa-
gaaagg uggguucuuc cugcgcauuc accccgaugg ccgugucgac ggcgucaggg
agaaguccga cccgcacaua aagcuccagc uccaggcuga ggagagaggg gucgug-
ucca ucaaaggggu gugcgccaau cgcuaucugg cgaugaagga ggacggcagg
cuccuggcua gcaagugugu gaccgacgag ugcuuucu uugagcggcu
ggaguccaac aacuacaaca ccuaccgaag ccgcaaguac acgagcuggu acgucg-
cacu gaagcggacu gggcaguaca agcugggcag caagacagga ccuggucaga ag-
gccauccu guuccugccc auguccgcca agagcuga

SEQ ID NO:22 FGF2

auggcagcag guaguauuac cacucuuccu gcuuugccug aagauggugg uucaggug-
cu uuuccuccag gucauucaa agauccaag agauuguauu gaaagaacgg aggau-

ucuuu cugagaauac acccagaugg cagaguugau gguguccgug aaaagucuga
uccucacauc aagcugcagc uucaagccga agagagggga guugugucua
ucaaaggugu gugugcuaau agauaccugg cuaugaaaga agaugguaga
cuucuggcau caaagugugu gacggaugaa ugcuuuuuu ucgagcguuu
ggaauccaac aauuacaaca cauaccguag cagaaaguac acaaguuggu auguug-
cacu gaaacgaaca ggucaguaua aacuggguuc uaaaacagga ccaggacaga ag-
gcgauuuu guuucuuccg augucugcua agucuuga

SEQ ID NO:23 FGF2

auggccgccc gcagcaucac caccugccc gccugcccg aggacggcgg
cagcggcgcc ucccccccg gccacucaa ggacccaag cgccuguacu gaa-
gaacgg cgguucuuc cugcgcaucc accccgacgg ccguguggac ggugugcgg
agaagagcga cccccacauc aagcugcagc ugcaggccga ggagcgcggc guggugag-
ca ucaagggcgu gugcgccaac cguaccugg ccaugaagga ggacggccgc
cugcuggcca gcaagugcgu gaccgacgag ugcuuucu ucgagcgcgu ggagag-
caac aacuacaaca ccuaccgag ccgcaaguac accagcuggu acguggcccu gaa-
gcgacc ggccaguaca agcugggag caagaccggc cccggccaga aggccauccu
guuccugccc augagcgcca agagcuaa

SEQ ID NO:24 FGF2

auggccgcug gcagcaucac aacauugccu gcucugccug aggauggcgg cucuggug-
cu uuuccaccug gccacucaa ggacccaag cgccuguacu gcaagaacgg cggau-
ucuuc cugcggauc accccgacgg aagaguggac ggugugcggg aaaaagcga
cccucacauc aagcuccagc ugcaggccga agagagaggc gucgucagua
ucaaaggcgu gugcgccaac agauaccugg ccaugaagga agauggccgg
cugcuggccu cuaagugcgu gaccgaugag ugcuuucu ucgaaacggcu ggaaa-
gcaac aacuacaaca ccuacagaag ccggaaguac accucuuggu acguggcccu
gaagcggacc ggccaguaua agcugggcuc uaagacaggc ccaggccaga ag-
gccauccu guuucugccu augagcgcca agagcuga

SEQ ID NO:25 FGF2

auggcagcag gcagcaucac uaccuugccc gccuuccgg aagaugggg aa-
gcggggccc uccccccag ggcacuuuaa ggauccgaag cgacuguaau guaaaaacgg
ggguucuuu cuucggaucc auccagaugg ccgaguagac gguguccgag aaaa-
gaguga cccccauauc aaacuucagc uccaggccga ggaaaggggu guggugagua
uaaagggggu gugcgcgaau cgauaccuug cuaugaagga ggacggucgc
cuucucgcca gaaaugcgu gacugacgag ugcuuuuuu ucgagcgaau
ggaauccaac aauuacaaca cauaccggag uagaaaauau accuccuggu au-
guagcgcg gaaaaggacc gggcaguaua agcucgggag uaaaaccggu cggggccaaa
aagcauacu guuucuucc augagcgcca aaucuga

SEQ ID NO:26 FGF2

auggccgcg gcucauaaac cacgcuuccu gcccgcccg aggacggggg aucaggug-
 ca uucccuccag gccacuuaa agauccaaa cgacuguacu gcaaaaacgg
 cggcuuuuuc uugcgaaucc aucccgacgg gagaguugau ggugucagag aaaaaa-
 guga cccgcacaua aagcuccaac ugcaagcggg agaaaggggc guugucucca uu-
 aaaggagu gugcgcgaau agguaccugg cuaugaagga ggacggacga uugcucgccu
 caaagugcgu aaccgaugag ugcuuuuuu ucgagcggcu cgaaucaaac aa-
 uacaaca cauaccgaag ccgcaaguac acgucuuggu acgucgccu gaagaggacg
 ggacaguaca aacucggguc aaaaaccggc cccggacaaa aggcuauccu
 cuuucuccu auguccgcaa aaucuuga

SEQ ID NO:27 FGF2

auggcagcug gcucuaauac uacgcugccc gcucucccug aggacggagg
 cuccggugcc uccccccag ggcacuuaa agauccaaa aggcuuuauu
 guaaaaacgg cggguuuuuu cuccggaucc accccgacgg ccgcguagau ggagug-
 aggg aaaagagcga ccucauuaa aaacugcagc ugcaggcuga ggagcgggga
 gucguuucga ucaaaggggu cugcgcgaaac cgcuaaccuug caaugaagga agacggaa-
 ga cuccuagcga guaaaugugu gacagaugaa ugcuucuucu uugagagacu
 ggaguccaau aauuaaaca ccuacagaag ccgaaaguau acuaguuggu acgug-
 gccu gaagcguacc ggucaauaca agcugggcuc uaagacaggu cccgggcaga ag-
 gccauuuu auucuugccu augucagcca agucauga

SEQ ID NO:28 FGF2

auggcagccg guucgauuac uaccuaccu gcccucccg aagauggugg aaguggcg-
 ca uuuccuccag gacauuuuaa ggaucacaaa ccgcuguacu gcaagaauug uggau-
 uuuu uuacgcauuc accccgaugg gcgagucgac gggguccgug aaaaguccga
 ccccacauc aaacuccagu ugcaagcuga ggagagaggc gugguuucaa
 ucaagggcgu augcgcuaau agauaucuug ccaugaagga ggacggggcg
 cuccuggccu caaaaugugu gacugacgag uguuuuuucu ucgagcggcu
 ggaauccaac aacuacaaca cauacaggag uagaaaauac accucuuggu augug-
 gcacu uaaaaggacg ggacaguuaa aguugggguc uaagacaggc ccuggccaga aa-
 gcgauacu guuccugccc augagcgua agagcuga

SEQ ID NO:29 FGF2

auggccgcag gcagcauac cacucuuccu gccuugccug aggacggugg uucaggug-
 cu uuuccuccag gucauuucaa agaccuaag cgacucuauu gcaagaacgg ag-
 gcuucuuu cugaggauac acccagacgg cagaguugac gguguccgug aaaagucuga
 uccucacauc aagcugcagc uucaagccga agagagggga guugugucua
 ucaaaggggu gugugcuaau cgguaccugg cuaugaaaga agaugguaga

cuccuggcau caaagugugu gacggaugag ugcuucuuuu ucgagcguuu
 ggaguccaac aauuacaaca ccuaccguag cagaaaguac accaguuggu augug-
 gcacu gaaacgaaca ggucaguaua aacuggguag caaacagga ccaggacaga ag-
 gcgauuuu guuucuuccg augucugcua agucuuga

SEQ ID NO:30 FGF7 consensus (optimized GC-rich sequences)

auggchgcng gcwshauhac hacnyubcch gchyukccb g argayggvvg hwsagg-
 bgch uuyccchchg gscacuuyaa rgayccsaar mgvcuguayu gyaaraaygg
 bggvuuyuy yukcgvauyc ayccmgaygg vmghgungay gghgusmgvg
 araarwshga yccbayaum aarcubcarc uscargcbga rgarmgvvgb gubgus-
 wsya uhaarggvgu gugygcsaay mgvuaycukg cbaugaarga rgayggmvg
 yubcusgcyw shaarugygu rachgaygag ugcuuyuyu uygarcgyu sgarws-
 maac aayuacaaca cmuaymgvag ymgvaaruay acswsyuggu aygungcvcu
 gaarmgsacb ggvcaguaya arcubggsws haaracmggh ccngghcara argchau-
 hcu suuyubccy augwsygma arwsyura

SEQ ID NO:31 FGF7 consensus (all optimized sequences)

auggchgcng gywsnauhac hacnyuncn gchyubccb g argayggng hwsagg-
 bgch uuyccchchg gncayuuyaa rgayccnaar mgvyubuayu gyaaraaygg
 nggvuuyuy yunmgvauhc ayccmgaygg vmghgungay ggngusmgng
 araarwshga yccbayaum aarcubcary ubcargcbga rgarmgvvgg gubgub-
 wsna uhaarggngu vugygnaay mgvuaycukg cnaugaarga rgayggnmvg
 yubcuvgnw shaarugygu racngaygar ugyuuyuyu uygarmgnyu sgarws-
 maay aayuayaaca cmuaymgnag ymgvaaruay acnwsyuggu aygungcvyu
 kaarmgnacn ggncaruaya aryubggbs haaracmggh ccnggncara argcnau-
 hyu vuuyubccb augwshgcha arwshura

SEQ ID NO:32 FGF2 consensus (all optimized and native sequences)

auggchgcng gbwsnauhac hacnyuncn gchyubccb g argayggng hwsagg-
 bgch uuyccncchg gncayuuyaa rgayccnaar mgvyubuayu gyaaraaygg
 nggvuuyuy yunmgvauhc ayccmgaygg vmghgungay ggngusmgng
 araarwshga yccbayaum aarcuncary ubcargcnga rgarmgvvgg gubgub-
 wsna uhaarggngu vugygnaay mgnuaycukg cnaugaarga rgayggnmvg yun-
 cuvgnw shaarugygu dacngaygar ugyuuyuyu uygarmgnyu sgarwshaay
 aayuayaaya chuaymgnws hmgvaaruay acnwsyuggu aygungcvyu
 kaarmgnacn ggncaruaya aryubggns haaracmggh ccnggncara argcnau-
 hyu nuuyubccn augwshgcha arwshura

SEQ ID NO:33 FGF2 protein

MAAGSITTLP ALPEDGGSGA FPPGHFKDPK RLYCKNGGFF LRIHPDGRVDG VREKSDPHIK

LQLQAEERGV VSIKGVCANR YLAMKEDGRL LASKCVTDEC FFFERLESNN YNTYRSRKYT
 SWYVALKRTG QYKLGSKTGP GQKAILFLPM SAKS

SEQ ID NO:34 RPL4_fwd primer sequence
 agcgtggctg tctcctctc

SEQ ID NO:35 RPL4_rev primer sequence
 gagccttgaa tacagcaggc

SEQ ID NO:36 ACTB_fwd primer sequence
 ggctgtattc ccctccatcg

SEQ ID NO:37 ACTB_rev primer sequence
 ccagttggta acaatgccat gt

SEQ ID NO:38 stabilization sequence
 yccanccwn ucycc

The consensus sequences SEQ ID Nos:12, 13, 14, 30, 31 and 32 are given with the following IUPAC nomenclature:

Table 1: IUPAC Nomenclature:

Symbol	Description	Bases represented		
A	<u>A</u> denine	A		
C	<u>C</u> ytosine	C		
G	<u>G</u> uanine	G		1
T	<u>T</u> hymine		T	
U	<u>U</u> racil		U	
W	W weak	A		T/U
S	S trong	C	G	
M	<u>a</u> M ino	A	C	
K	<u>K</u> eto		G	T/U ²
R	<u>pu</u> R ine	A	G	
Y	<u>p</u> Y rimidine		C	T/U
B	not A (B comes after A)	C	G	T/U
D	not C (D comes after C)	A	G	T/U ³
H	not G (H comes after G)	A	C	T/U
V	not T (V comes after T and U)	A	C	G

N any **N**ucleotide (not a gap) A C G T/U 4
Z Zero 0

Table 2:

Sequence ID	CAI (Human /HEK)	GC Content %
18	0,76	51,70
19	0,80	52,13
20	0,93	57,90
21	0,87	61,11
22	0,72	44,00
23	0,99	67,30
24	0,92	58,10
25	0,75	53,20
26	0,74	52,60
27	0,76	51,50
28	0,76	50,74
29	0,77	49,10

Table 2: Codon Adaptation Index and GC content of FGF2 variants (SEQ ID NO:1 is the standard for expression; SEQ ID NOs:2, 3 and 5: higher; SEQ ID NO:4: lower; it is therefore preferred to have a CAI $\geq 0,77$ and a GC content $\geq 51,7\%$; compared to the native sequences SEQ ID NOs:1, 18 and 28).

Table 3:

Sequence ID	CAI (Human /HEK)	GC Content %
1	0,74	39,5
2	0,81	47,17
3	0,94	55,00
4	0,89	56,92
5	0,75	39,70
6	1,00	57,60
7	0,99	61,20
8	0,79	43,20
9	0,79	46,70

10	0,71	42,90
11	0,74	44,60

Table 3: Codon Adaptation Index and GC content of FGF7 variants (SEQ ID NO:1 is the standard for expression; SEQ ID NOs:2, 3 and 5: higher; SEQ ID NO:4: lower; it is therefore preferred to have a CAI $\geq 0,74$ and a GC content $\geq 39,5\%$; compared to the native sequences SEQ ID NOs:1, 18 and 28).

The invention is further explained by way of the following examples and the figures, yet without being limited thereto.

Figure 1 shows the RT-PCR based detection of IVT mRNA 24-120h post transfection of murine 3T3 cells (24-120h: samples taken 24-120h post transfection; 0 μ g: cells were treated with TransIT only and harvested 24h post transfection; H₂O: negative control containing no cDNA.; pos. control: cDNA from cellular RNA and IVT mRNA variants; empty cells: non-transfected 3T3 fibroblasts). SEQ ID NOs:1-4: analysis of respective human FGF7 IVT mRNA variants; SEQ ID NOs:18-21: analysis of respective human FGF2 IVT mRNA variants.

Figure 2 shows the RT-PCR based detection of IVT mRNA 24-120h post transfection of human BJ cells (24-120h: samples taken 24-120h post transfection; 0 μ g: cells were treated with TransIT only and harvested 24h post transfection; H₂O: negative control containing no cDNA.; pos. Control: cDNA from cellular RNA and IVT mRNA variants; empty cells: non-transfected fibroblasts). SEQ ID NOs:1-4: analysis of respective human FGF7 IVT mRNA variants; SEQ ID NO:18-21: analysis of respective human FGF2 IVT mRNA variants.

Figure 3 shows that IVT mRNA transfection of codon and GC content optimized FGF2 mRNA variants induces increased human FGF2 protein expression in murine 3T3 fibroblasts (SEQ ID NO: respective FGF2 mRNA sequence complexed with TransIT; TransIT: TransIT mRNA transfection reagent only; ctrl: buffer only; A: analysis at 24h and 72h post transfection; B: analysis at 120h post transfection).

Figure 4 shows that IVT mRNA transfection of codon and GC content optimized FGF7 mRNA variants induces increased human FGF7 protein expression in murine 3T3 fibroblasts (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; TransIT:

TransIT mRNA transfection reagent only; ctrl: buffer only; Analysis at 72h post transfection.

Figure 5 shows that IVT mRNA transfection of codon and GC content optimized FGF2 mRNA variants induces increased human FGF2 protein expression in human BJ fibroblasts (SEQ ID NO: respective FGF2 mRNA sequence complexed with TransIT; TransIT: TransIT mRNA transfection reagent only; ctrl: buffer only; Analysis at 24h post transfection (A) and 120h post transfection (B); error bars indicate SEM (samples analysed: n≤6).

Figure 6 shows that IVT mRNA transfection of codon and GC content optimized FGF7 mRNA variants induces increased human FGF7 protein expression in human BJ fibroblasts (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; TransIT: TransIT mRNA transfection reagent only; ctrl: buffer only; Analysis at 48h post transfection.

Figure 7 shows that IVT mRNA transfection of codon and GC content optimized mRNA variants induces increased human FGF2 protein expression in porcine skin epithelial sheets (SEQ ID NO: respective FGF2 mRNA sequence complexed with TransIT; TransIT: TransIT mRNA transfection reagent only; TransIT GFP: eGFP mRNA sequence complexed with TransIT; ctrl: buffer only; Analysis at 24h (A), 48h (B) and 72h (C) post transfection.

Figure 8 shows that IVT mRNA transfection of codon and GC content optimized mRNA variants induces increased human FGF7 protein expression in porcine skin epithelial sheets (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; TransIT: TransIT mRNA transfection reagent only; TransIT GFP: eGFP mRNA sequence complexed with TransIT; ctrl: buffer only; A: analysis at 24h post transfection.

Figure 9 shows that EGFP mRNA transfection of porcine epithelial sheets using TransIT mRNA transfection reagent induces eGFP expression in porcine skin epithelial sheets (A: porcine skin transfected with liposomes only; B: porcine skin transfected with 0,5µg/ml eGFP IVTm RNA, formulated in TransIT; C: porcine skin transfected with 1µg/ml eGFP IVTm RNA, formulated in TransIT).

Figure 10 shows that eGFP mRNA transfection of porcine epithelial sheets using mRNA/Liposome complexes induces eGFP expression in porcine skin epithelial sheets (A: porcine skin transfected with liposomes only; B: porcine skin transfected

with 2µg/ml eGFP IVTm RNA, formulated in liposomes; C: porcine skin transfected with 10µg/ml eGFP IVTm RNA, formulated in liposomes).

Figure 11 shows the detection of whole mount β-Galactosidase (bGal) activity in porcine skin explants 24h after transfection with LacZ IVT mRNA (A: porcine skin transfected with DOTAP-liposomes only w/o Rnase inhibitor; B: porcine skin transfected with 5µg LacZ IVTm RNA, formulated in DOTAP-liposomes w/o Rnase inhibitor; C: porcine skin transfected with DOTAP-liposomes only + Rnase inhibitor; D: porcine skin transfected with 5µg LacZ IVTm RNA, formulated in DOTAP-liposomes w/o Rnase inhibitor; successful transfection is highlighted in encircled areas in B and D, respectively).

Figure 12 shows the detection of eGFP expression in porcine skin explants 24h after transfection with eGFP IVT mRNA (untreated: non-treated biopsy; LNP ctrl: porcine skin LNP control treated; eGFP-LNP: porcine skin transfected with mRNA-Lipid-Nano Particles (concentration shown: 2.5µg eGFP mRNA/dose); eGFP 2.5µg, eGFP 5µg and eGFP 10µg: porcine skin transfected with non-complexed eGFP IVT-mRNA (concentrations shown: 2,5+5+10µg mRNA/dose); buffer ctrl porcine skin treated with buffer only).

Figure 13 shows the detection of Firefly Luciferase (FLuc) expression in porcine skin epithelial sheets 24h after transfection with FLuc IVT mRNA (1µg mRNA/transfection) Porcine skin was transfected with 2 different liposomes only (L1 and L2 only) or Liposome mRNA complexes using a high Lipid to mRNA ratio (Fluc HL, high lipid) or a low lipid to mRNA ratio (Fluc LL, low lipid); Fluc mRNA complexed (TransIT Fluc) or non-complexed TransIT (TransIT only) was used as control A: Bioluminescence detection in a 96 well plate; B: detection of Luminescence units on an Tecan Infinite Luminescence reader.

Figure 14 shows the detection of Firefly Luciferase (FLuc) expression in porcine skin explants 24h after transfection with FLuc IVT mRNA (1µg mRNA/transfection) Porcine skin was transfected with liposomes only (L only) or Liposome mRNA complexes using a high Lipid to mRNA ratio (L Fluc (High lipid)) or a low lipid to mRNA ratio (L Fluc (Low Lipid)); Fluc mRNA complexed (TransIT Fluc) or non-complexed TransIT (TransIT only) was used as control A: detection of Luminescence units from epithelial sheets 24h post transfection; B: detection of Luminescence units

from dermal explants 24h post transfection.

Figure 15 shows that IVT mRNA transfection of native FGF7 mRNA using non modified nucleotides induces increased human FGF7 protein expression in murine 3T3 fibroblasts as compared to a IVT mRNA containing modified nucleotides (exchange of C and 5meC as well as U and pseudoU nucleotides during in vitro transcription) (SEQ ID1: non modified FGF7 mRNA sequence complexed with TransIT; Seq ID1_mn: non modified FGF7 mRNA sequence containing modified nucleotides complexed with TransIT TransIT: TransIT mRNA transfection reagent only; Analysis at 24h post transfection.

Figure 16 shows that IVT mRNA transfection of codon and GC content optimized FGF2 mRNA variants induces increased hyaluronic acid synthesis in murine 3T3 fibroblasts (SEQ ID NO: respective FGF2 mRNA sequence complexed with TransIT; TransIT: TransIT mRNA transfection reagent only;) Analysis has been performed at 24h and 72h post transfection.

Figure 17 shows that in contrast to IVT mRNA induced protein, recombinant FGF protein is unstable in 3T3 cells and porcine primary fibroblasts 24h after transfection/addition. No remaining or newly synthesized FGF protein is detectable in all 4 experiments in the samples receiving rec. FGF proteins. SEQ ID NO: respective FGF2 and FGF7 mRNA sequence complexed with TransIT; rec. FGF2/7 1ng/ml: cells were exposed to recombinant FGF2 or FGF7 protein (1ng/ml); Analysis at 24h post transfection/protein addition; (A) FGF2 levels in 3T3 cells; (B) FGF2 levels in porcine primary fibroblasts; (C) FGF7 levels in 3T3 cells; (D) FGF7 levels in porcine primary fibroblasts.

Figure 18 shows that shows that IVT mRNA transfection of codon and GC content optimized mRNA variants of human FGF7 induces increased hyaluronan secretion in porcine cells (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; TransIT: TransIT mRNA transfection reagent only; rec. FGF7: recombinant FGF7 protein added for the culture period (1ng/ml); neg. ctrl: buffer only); analysis from supernatant taken at 48h post transfection.

Figure 19 shows that IVT mRNA transfection of codon and GC content optimized mRNA variants of human FGF7 induces increased hyaluronan secretion in porcine epithelial sheets (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; neg. ctrl:

buffer only); analysis from supernatant taken at 24h post transfection.

Figure 20 shows that IVT mRNA transfection of codon and GC content optimized mRNA variants of human FGF2 induces increased hyaluronan secretion in porcine cells (SEQ ID NO: respective FGF2 mRNA sequence complexed with TransIT; TransIT: TransIT mRNA transfection reagent only; rec. FGF2: recombinant FGF2 protein added for the culture period (1ng/ml); neg. ctrl: buffer only); analysis from supernatant taken at 48h post transfection.

Figure 21 shows that shows that IVT mRNA transfection of codon and GC content optimized mRNA variants of human FGF2 induces increased hyaluronan secretion in porcine epithelial sheets (SEQ ID NO: respective FGF2 mRNA sequence complexed with TransIT; neg. ctrl: buffer only); analysis from supernatant taken at 24h post transfection.

Figure 22: shows that IVT mRNA transfection of codon and GC content optimized mRNA variants of FGF7 induces increased human FGF7 protein expression in porcine skin cells (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; neg. ctrl: buffer only); analysis at 24h and 48h post transfection.

Figure 23: shows that IVT mRNA transfection of codon and GC content optimized FGF7 mRNA variants induces increased human FGF7 protein expression in murine 3T3 fibroblasts (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; neg. ctrl: buffer only); Analysis at 24h and 48h post transfection.

Figure 24: shows that IVT mRNA transfection of codon and GC content optimized FGF7 mRNA variants induces increased human FGF7 protein expression in murine 3T3 fibroblasts (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; neg. ctrl: buffer only); Analysis at 24h and 48h post transfection.

Figure 25: shows that IVT mRNA transfection of codon and GC content optimized FGF7 mRNA variants induces increased human FGF7 protein expression in human dermal fibroblasts (BJ cell line) (SEQ ID NO: respective FGF7 mRNA sequence complexed with TransIT; neg. ctrl: buffer only); Analysis at 48h and 72h post transfection.

Figure 26: Porc Fibs FGF2 shows that IVT mRNA transfection of codon and GC content optimized mRNA variants of FGF2 induces increased human FGF2 protein expression in porcine skin cells (SEQ ID NO: respective FGF2 mRNA sequence complexed with Trans-

IT; neg. ctrl: buffer only); analysis at 24h and 48h post transfection.

Figure 27: shows that IVT mRNA transfection of codon and GC content optimized FGF2 mRNA variants induces increased human FGF2 protein expression in murine 3T3 fibroblasts (SEQ ID NO: respective FGF2 mRNA sequence complexed with TransIT; neg. ctrl: buffer only); Analysis at 48h post transfection.

Figure 28: shows that IVT mRNA transfection of codon and GC content optimized FGF2 mRNA variants induces increased human FGF2 protein expression in human dermal fibroblasts (BJ cell line) (SEQ ID NO: respective FGF2 mRNA sequence complexed with TransIT; neg. ctrl: buffer only); Analysis at 48h post transfection.

EXAMPLES:

Material and methods:

Transfection of murine 3T3 fibroblasts and human B.J. skin fibroblasts

For transfection, murine 3T3 fibroblasts and human B.J. skin fibroblasts were seeded at $4-6 \times 10^4$ cells/well in 12-well plates. After 24 hours incubation in full EMEM or DMEM medium (Gibco, Thermo Fisher, USA), culture medium was replaced. Different formulations of IVT mRNA complexed with TransIT mRNA transfection reagent (Mirus Bio; complex formation according to manufacturer instructions) were prepared and added to the cells. 24 hours after transfection, medium was replaced with complete DMEM. Cell cultures were maintained under standard conditions for up to 5 days with daily medium changes until evaluation.

Isolation and transfection of intact pig skin biopsies:

Full-thickness porcine skin flaps were isolated perimortally from pigs (samples were obtained in full compliance with national legislation (i.e. Tierversuchsgesetz 2012, TVG 2012 (BGBl. I Nr. 114/2012))) and disinfected using Octenisept® disinfectant (Schuelke + Mayr GmbH, Germany).

Transfection of intact pig skin was performed by direct, intradermal injection of the IVT mRNA solution (1-10µg mRNA/dose).

LacZ IVT mRNA (completely modified using 5-methylcytidine, pseudouridine; Trilink Inc., USA) was formulated using either TransIT[®]-mRNA Transfection kit (Mirus Bio[™]) according to manufacturer instructions (with slight modification according to Kariko et al.; Mol. Ther. 2012. 20(5): 948-53) or DOTAP based liposomal formulations (Sigma Aldrich, USA). DOTAP based formulations were prepared using a lipid/RNA ratio of 5/1 ($\mu\text{g}/\mu\text{g}$). In addition, mRNA complexes were also supplemented with RNase Inhibitor (5U/dose, RNasin, Promega, USA). Injection volume ranged from 20 μL to 30 μL .

Alternatively, transfection of intact pig skin was performed by direct, intradermal injection of eGFP IVT mRNA solution (0.5-25 μg mRNA/dose). eGFP IVTmRNA (AMPTec, Germany) was formulated using either TransIT[®]-mRNA Transfection kit (Mirus Bio[™]) according to manufacturer instructions (with slight modification according to Kariko et al., 2012, or DOTAP based liposomal formulations (Sigma Aldrich, USA), or Lipid-Nano-particle formulations (Polymun, Austria) or SAINT based liposomal formulations (Synvolux, Netherlands). DOTAP based liposomal formulations were prepared using a lipid/RNA ratio of 5/1 ($\mu\text{g}/\mu\text{g}$). SAINT lipid based formulations were prepared using a lipid/RNA ratio of 2.5-4/1 ($\mu\text{g}/\mu\text{g}$). In addition, non-complexed mRNA in physiologic buffer was applied intradermally with an injection volume range from 20 μL to 30 μL .

After injection, punch biopsies of the injected areas (8mm diameter) were sampled, subcutaneous fat was removed and biopsies were transferred into standard complete culture medium in a petridish, epidermis facing the air-liquid interface (5mL; containing: Dulbecco's Modified Eagle Medium with GlutaMAX (DMEM), 10% FCS, 1X Penicillin-Streptomycin-Fungizone; obtained from Gibco, Life Technologies). Subsequent culture was performed at 37°C/5% CO₂ for 24 hours, at which point biopsies were normally harvested.

Isolation and transfection of porcine epithelial sheets and dermal explants

Full-thickness porcine skin flaps were isolated perimortally from pigs (samples were obtained in full compliance with national legislation (i.e. Tierversuchsgesetz 2012, TVG 2012)) and disinfected using Octenisept[®] disinfectant (Schuelke +

Mayr GmbH, Germany). Punch biopsies (6 or 8 mm diameter) were harvested from full-thickness skin flaps, subcutaneous fat removed, and biopsies were cut in two parts. Immediately afterwards, cut biopsies were transferred, epidermis facing the air-liquid interface, to 9 cm (diameter) petri-dishes containing 5 mL Dispase II digestion solution (ca. 2.5 Units/mL; Dispase II; Sigma Aldrich, USA). Subsequent digestion was performed at 4°C overnight. Dispase II digestion solution was prepared by diluting Dispase II stock solution (10 mg/mL in 50mM HEPES/150 mM NaCl; pH-7.4) 1:2 with 1x DMEM (Gibco) and adding 1x Penicillin/Streptomycin. Epidermal sheets were then separated from the underlying dermis (i.e. dermal explants) using forceps and transferred into DMEM for a short (5 min.) washing step. Subsequently sheets and dermal explants were put into complete DMEM culture medium and incubated at 37°C/5% CO₂ (6 to 8 hours) until transfection was performed in 24-well culture plates. Transfection of porcine epidermal sheets and dermal explants was performed using eGFP IVT mRNA (AmpTec, Germany), Firefly Luciferase (FLuc) IVT mRNA or IVT mRNA constructs for FGF (e.g.: SEQ ID NOs:1-4 and 18-21). mRNA was formulated using either TransIT[®]-mRNA Transfection kit (Mirus Bio[™]) according to manufacturer instructions or liposomal formulations (Polymun, Austria) or SAINT based liposomal formulations (Synvolux, Netherlands). SAINT lipid based formulations were prepared using a lipid/RNA ratio of 2.5 (µg/µg) (Low Lipid formulation) or 4/1 (µg/µg) (High Lipid formulation). Liposomal formulations were prepared using a lipid/RNA ratio of 5/1 (µg/µg). All lipoplex solutions for transfection contained 0.1µg to 10µg mRNA/mL DMEM medium and epidermal sheets and dermal explants were cultured one to three days.

For analysis, tissue culture supernatants were collected for ELISA analysis. Sheets were harvested for RNA and protein extraction and subsequent analysis by qPCR and ELISA, respectively. eGFP transfected epidermal sheets were also analysed for eGFP expression by direct fluorescence microscopy and immunohistochemistry detecting eGFP in situ. FLuc transfected epidermal sheets and dermal explants were analysed for Luciferase activity on a Tecan Infinite multimode reader.

RT-PCR analysis of cells transfected using IVT mRNA preparations

Human B.J. cells and murine 3T3 fibroblasts were transfected

using 1µg FGF2 or FGF7 IVT mRNAs complexed with TransIT mRNA transfection reagent. Total cellular RNAs were isolated from murine and human fibroblasts or porcine epithelial sheets at different time points post transfections using Tri-Reagent (Thermo Fisher, USA, according to manufacturer instructions) and mRNAs were reverse transcribed into cDNA by conventional RT-PCR (Protoscript First Strand cDNA synthesis kit, New England Biolabs, according to manufacturer instructions). cDNA samples were then subjected to conventional PCR and qPCR. Primers were obtained from Invitrogen.

PCR analysis detecting FGF variants was performed from cDNA obtained from cells and/or sheets transfected with different FGF2 and FGF7 variants using Platinum Taq Polymerase (Invitrogen, USA) and FGF variant specific primers (Invitrogen, USA). Primers for native FGF2 mRNA have been obtained from Biorad (USA). Human RPL4 and murine ACTB (Eurofins Genomics) were used as positive controls. PCR products were analysed using conventional agarose gel electrophoresis. qPCR was performed using the Luna® Universal qPCR Master Mix (New England Biolabs, USA, according to manufacturer's protocol) on a CFX Real-Time PCR Detection System (Biorad). Level and stability of IVT mRNAs was determined relative to internal standards to normalize for variances in the quality of RNA and the amount of input cDNA (e.g.: murine ACTB or human RPL4, respectively)

Table 4: PCR primers

Primer (Producer, SEQ ID NO:)	Sequence
huRPL4_fw (EG, 34)	5'-AGC GTG GCT GTC TCC TCT C-3'
huRPL4_rev (EG, 35)	5'-GAG CCT TGA ATA CAG CAG GC-3'
muACTB_fw (EG, 36)	5'-GGC TGT ATT CCC CTC CAT CG-3'
muACTB_rev (EG, 37)	5'-CCA GTT GGT AAC AAT GCC ATG T-3'
F2_hum_3 fw (IVG,38)	5'-CGT GTA GAC GGA GTC AGG GA-3'
F2_hum_3 rev (IVG, 39)	5'-GCA CAC ACC CCT TTG ATG GA-3'
F2_GC_3 fw (IVG, 40)	5'-GCC TGT ACT GCA AGA ACG GT-3'
F2_GC_3 rev (IVG, 41)	5'-CTG GAG CTT TAT GTG CGG GT-3'

F7_hum_1 fw (IVG, 42)	5'-TTC GCA TCG ACA AAC GGG GT-3'
F7_hum_1 rev (IVG, 43)	5'-GCG ACA ATC CCG ACT GCA AC-3'
F7_GC_3 fw (IVG, 44)	5'-TGC ACA AGT GGA TCC TCA CA-3'
F7_GC_3 rev (IVG, 45)	5'-CCA GTG AGA TAG TGC CCA CC-3'
F7_nat_2 fw (IVG, 46)	5'-TGA ACT GTT CCA GCC CTG AG-3'
F7_nat_2 rev (IVG, 47)	5'-TCA GGT ACC ACT GTG TTC GAC-3'

EG: Eurofins Genomics, IVG: Invitrogen

Analysis of IVT mRNA induced human FGF2 and FGF7 protein

Murine 3T3 cell, human B.J. cells, porcine primary fibroblasts and porcine epithelial sheets were transfected using 0.1-1µg IVT mRNA for different FGF2 and FGF7 variants complexed with TransIT mRNA transfection reagent and cultured for up to 120h post transfection. Supernatants from transfected cells and epithelial sheets were obtained at several time points after transfection; cells were harvested at the same time points and protein was extracted. Protein was extracted using a cell extraction buffer (10mM HEPES, 10mM KCl, 0.1µM EDTA, 0.3% NP40 and Roche Protease Inhibitor, according to manufacturer's protocol). FGF determination in supernatants was performed using human FGF2 and FGF7 ELISA kits (Duo Set ELISA kits, R and D systems, Biotechne, USA, according to manufacturer's instructions), and measured on an Infinite 200 PRO multimode reader (Tecan AG, Switzerland).

Analysis of IVT mRNA induced eGFP protein

Intact porcine skin explants and porcine epithelial sheets were transfected using 0.1-10µg eGFP IVT mRNA complexed with TransIT mRNA transfection reagent or different liposomal carriers or uncomplexed ("naked" in physiologic buffer) and cultured for 24h post transfection. Samples were harvested and protein extracted using cell extraction buffer (10mM HEPES, 10mM KCl, 0.1µM EDTA, 0.3% NP40 and Roche Protease Inhibitor, according to manufacturer's protocol). eGFP determination was performed using the GFP in vitro SimpleStep ELISA® kit (Abcam Plc., UK, according to manufacturer instructions), and measured on an Infinite 200 PRO multimode reader (Tecan AG, Switzerland).

Detection of beta-galactosidase activity in porcine tissue

Whole-mount beta-galactosidase (bGal) staining of biopsies was performed in 24 well culture plates for 24 or 48 hours at 37°C. Positive staining controls were generated by injecting bGal enzyme (1U recombinant bGal protein/ injection) intradermally into pig skin. Before staining, biopsies were mildly fixed in a 4% formaldehyde solution with PBS for 1 hour at room temperature. After fixation, samples were washed in PBS (3x) and subsequently equilibrated in LacZ-washing buffer (2mM MgCl₂, 0.01% Na-deoxycholate and 0.02% NP-40 dissolved in PBS). After equilibration, samples were stored overnight (4°C). Samples were then incubated in staining solution at 37°C and the colour reaction monitored. The staining solution was freshly prepared (5mM K₄Fe(CN)₆ and 5mM K₃Fe(CN)₆ in LacZ buffer) and 1 mg/mL 5-Bromo-3-indolyl β-D-galactopyranoside, (Bluo-Gal) was added as colour substrate. If staining was performed for 48 hours the staining solution was substituted after 24 hours. Staining volume was generally 0.5 mL/well. Staining was stopped by washing in LacZ washing buffer and 3x PBS. Samples were subsequently either fixed overnight in buffered 4% formaldehyde solution and further processed for standard histology or were frozen in optimal cutting temperature compound (OCT) for subsequent histologic analyses.

Analysis of IVT mRNA induced FLuc protein

Porcine epithelial sheets and dermal explants were transfected using 2µg/ml FLuc IVT mRNA complexed with TransIT mRNA transfection reagent or SAINT lipid based formulations and cultured for 24h post transfection. Samples were harvested and subjected to direct Luciferase activity measurement. Measurements were performed using Firefly Luc One-Step Glow Assay Kit (Thermo Scientific, USA, according to manufacturer's instructions) and analysed on an Infinite 200 PRO multimode reader (Tecan AG, Switzerland). In addition, samples were also assessed on a GelDoc-system directly detecting Luminescence.

Analysis of IVT mRNA induced secretion of Hyaluronic acid

Murine 3T3 cells were seeded at 5 x 10⁴ cells/well in 12-well plates. After 24 hours incubation in full DMEM medium (Gib-

co, Thermo Fisher, USA), culture medium was replaced. Different formulations of IVT mRNA encoding for FGF2 and FGF7 complexed with TransIT mRNA transfection reagent (Mirus Bio; complex formation according to manufacturer instructions) were prepared and added to the cells.

For analysis of Hyaluronic acid secretion, supernatant from transfected cells was obtained 24 to 120h hours after transfection. Supernatants were subjected to analysis of FGF induced Hyaluronan production using the Hyaluronan Quantikine ELISA Kit (R and D systems, Biotechne, USA, according to manufacturer's instructions). ELISA measurements were taken on an Infinite 200 PRO multimode reader (Tecan AG, Switzerland).

Transfection of porcine primary skin fibroblasts

For transfection, porcine primary skin fibroblasts were seeded at 5×10^3 cells/well in 96-well plates. After 24 hours incubation in full FGM-2 Fibroblast medium (LONZA, Switzerland), culture medium was replaced with complete DMEM. Different formulations of IVT mRNA complexed with TransIT mRNA transfection reagent (Mirus Bio; complex formation according to manufacturer instructions) were prepared and added to the cells. 24 hours after transfection, medium was replaced with complete DMEM. Cell cultures were maintained under standard conditions for up to 2 days with daily medium changes until evaluation.

Example 1: Detection of mRNA encoding different FGF2 and FGF7 variants by FGF-variant specific PCR from cDNA obtained from murine 3T3 fibroblast cells 24h-120h post transfection.

In order to assess whether FGF2 and FGF7 mRNA variants are stable in murine fibroblasts over prolonged time periods, different mRNAs encoding SEQ ID NOs:1-4 and 18-21 were used to transfect 3T3 cells. RNA was isolated at different time points (24-120h post transfection) and the presence of mRNA in transfected cells determined up to 120h post transfection by non-quantitative RT PCR.

Result: As shown in Figure 1, all FGF mRNA variants can be detected following transfection using $1\mu\text{g}$ mRNA/ml at all time points assessed, showing mRNA stability, irrespective of codon optimization or GC content in human cells for $\geq 120\text{h}$.

Figure 1 shows 3T3 cells transfected without mRNA, or with 1µg mRNA complexed with TransIT mRNA transfection reagent. Total cellular RNAs were isolated at different time points after transfection (24h-120h) and mRNAs were reverse transcribed into cDNA by conventional RT-PCR. cDNA samples were then subjected to variant specific PCR using primers for SEQ ID NOs:1-4 and 18-21 for the detection of transfected FGF2 and FGF7 mRNAs and murine ACTB as a PCR control (shown as ctr). All FGF variants were stable over extended time periods in murine cells. It follows that there is differential expression and/or secretion of FGF as determined by the codon adaptation index (CAI) and GC content.

Example 2: Detection of mRNA encoding different FGF2 and FGF7 variants by FGF-variant specific PCR from cDNA obtained from fibroblast cells 24h-120h post transfection.

In order to assess whether FGF mRNA variants are stable in human skin fibroblasts over prolonged time periods, different mRNAs encoding SEQ ID NOs:1-4 and 18-21 were used to transfect B.J. cells. RNA was isolated at different time points (24-120h post transfection) and the presence of mRNA in transfected cells was determined up to 120h post transfection by non-quantitative RT-PCR.

Result: As shown in Figure 2, all FGF mRNA variants can be detected following transfection using 1µg mRNA/ml at all time points assessed, showing mRNA stability, irrespective of codon optimization or GC content in human cells for ≥120h.

Figure 2 shows B.J. cells transfected without mRNA, or 1µg mRNA complexed with TransIT mRNA transfection reagent. Total cellular RNAs were isolated at different time points after transfection (24h-120h) and mRNAs were reverse transcribed into cDNA by conventional RT-PCR. cDNA samples were then subjected to variant specific PCR using primers for SEQ ID NOs:1-4 and 18-21 for detection of transfected FGF mRNAs and human RPL4 as PCR control (shown as ctr). All FGF variants were stable over extended time periods in human cells. mRNA was also detectable for extended time in porcine epithelial sheets. It follows that there is differential expression and or secretion of FGF2 and FGF7 according to CAI and GC content.

Example 3: Assessment of levels of human FGF2 protein by protein

ELISA from cell culture supernatants of murine 3T3 fibroblast cells 24h, 72h and 120h post transfection with human FGF2 IVT mRNA variants.

In order to assess whether codon optimization for optimal translation efficiency in the human system (as determined by the CAI) and a concomitant increase of GC content in the coding sequence (CDS) of FGF2 mRNA variants led to expression changes in human FGF2 protein, 3T3 fibroblasts were transfected with different FGF2 mRNA variants. mRNAs encoding SEQ ID NOs:18, 19 and 21 were used to transfect 3T3 cells. Subsequently, the level of secretion of human FGF2 from transfected cells was determined for up to 120h post transfection.

Result: All 3 FGF2 mRNA variants are inducing high levels of human FGF2 protein using 1 μ g mRNA/ml at all time points assessed (Figure 3). Comparative analysis of IVT mRNA encoding for native human FGF2 and the two variants showed an unexpected combined effect of codon optimization (i.e. CAI levels $\geq 0,76$) and an increase of GC content (GC content $\geq 51,7\%$) in the CDS of the mRNA. Figure 3 shows 3T3 cells (4×10^4 - 5×10^4 /well) transfected using IVT mRNAs complexed with TransIT mRNA transfection reagent (1 μ g mRNA/ml). Supernatants were obtained and subjected to human FGF2 specific protein ELISA (R and D Systems). Values depicted are measured as pg/ml FGF2 protein.

Those sequences which were above the threshold (CAI ≥ 0.76 and GC content $\geq 51,7\%$) induced significantly higher expression levels of FGF2 at early and late stages showing a surprisingly high benefit over native sequences in the amplitude and longevity of gene expression.

Surprisingly, transfection of fibroblasts with the optimized FGF mRNA variants, provided with the present invention, differs in terms of its overall kinetics from what is known in the field about other mRNAs:

Upon delivery of previously described IVT mRNA into a given cell, the internalized IVT mRNA content will continuously drop after an initial peak level, which is usually followed by a delayed drop in protein translation. Surprisingly, and in sharp contrast to the usual situation described above, delivery of the present invention, FGF mRNA variants, into cells is characterized by a dissociation between the mRNA and protein kinetics. Specifically, while the IVT mRNA is gradually degraded upon de-

livery, protein secretion as shown here (Figures 3-8) begins to rise on the first day (i.e. expression is lowest for the first 24h). It then reaches a plateau on the second day, which is sustained for several days before FGF production wanes. Importantly, this novel pattern was obtained with 3 different cell lines of two origins from three species. Moreover, it is consistent with an effect of IVT mRNA-induced FGF protein on the auto- or paracrine regulation of endogenous FGF production.

The optimized sequences according to the present invention therefore have i.a. a very surprising effect compared to the native sequences and to the recombinant protein:

With the optimized sequences of FGF2 and FGF7, a significant prolongation of the effect can be obtained. The observed activity of the native and the optimized sequences is comparable, but not reaching a plateau yet, in the initial 24h phase after transformation in 3T3 cells (Figure 3). However, this changes significantly in the further course of the experiment. The native sequence is able to increase expression as shown by analysis at 72h, but it does not induce significant activity after 120 h. In contrast, the optimized sequences, as provided with the present invention, induce increased expression in 3T3 cells after 72h and also, surprisingly, produce a 10-fold to almost 100-fold improved effect at 120h post transfection in this example (Figure 3). Moreover, it has to be emphasized that levels detectable after 120h are even higher than after 24h. Similar patterns have also been obtained in BJ cells (e.g.: Figure 5, with a significantly higher level of protein present at 120h as compared to 24h especially for SEQ ID NO:21) or in porcine epithelial sheets, where levels are increasing significantly at 48h and 72h as compared to the native sequence (see Figure 7). Interestingly, this pattern is not achieved upon addition of recombinant FGF protein at similar amounts as expressed at 24h post transfection to the cells/organs. Therefore, no such auto-regulation has been observed 24h post addition of recombinant FGF protein suggesting that mRNA-induced expression is able to activate different intra- and extracellular effects compared to protein substitution.

Example 4: Assessment of levels of human FGF7 protein by protein ELISA from cell culture supernatants of murine 3T3 fibroblast

cells up to 120h post transfection with human FGF7 IVT mRNA variants.

In order to assess whether codon optimization for optimal translation efficiency in the human system (as determined by the CAI) and concomitant increase of GC content in the CDS of FGF7 mRNA variants changes expression of human FGF7 protein, 3T3 fibroblasts were transfected with different FGF7 mRNA variants. mRNAs encoding SEQ ID NOs:1, 2 and 4 were used to transfect 3T3 cells. Subsequently, the level of secretion of human FGF7 from transfected cells was determined for up to 120h post transfection.

Result: All 3 FGF7 mRNA variants induced high levels of human FGF7 protein using 1µg mRNA/well at all time points assessed (Figure 4). Comparative analysis of IVT mRNA encoding for native human FGF4 and the two variants showed an unexpected combined effect of codon optimization ($CAI \geq 0.74$) and an increase of GC content (GC content $\geq 39,5\%$) in the CDS of the mRNA. Figure 4 shows 3T3 cells ($4 \cdot 10^4 - 5 \cdot 10^4$ /well) transfected using IVT mRNAs complexed with TransIT mRNA transfection reagent (1µg mRNA/ml). Supernatants were obtained and subjected to human FGF7 specific protein ELISA (R and D Systems). Values depicted are measured as pg/ml FGF7 protein.

Those sequences which were above the threshold ($CAI \geq 0.74$ and GC content $\geq 39,5\%$) induced significantly higher expression levels of FGF7 at early and late stages showing a surprisingly high benefit native sequences in the amplitude and longevity of expression.

Example 5: Assessment of levels of human FGF2 protein by protein ELISA from cell culture supernatants of human B.J. fibroblast cells up to 120h post transfection with human FGF2 IVT mRNA variants.

In order to assess whether codon optimization for optimal translation efficiency in the human system (as determined by the CAI) and concomitant increase of GC content in the CDS of FGF2 mRNA variants changes expression of human FGF2 protein, B.J. fibroblasts were transfected with different FGF2 mRNA variants. mRNAs encoding SEQ ID NOs:18, 19 and 21 were used to transfect BJ cells. Subsequently, the level of secretion of human FGF2 from transfected cells was determined for up to 120h post trans-

fection.

Result: All 3 FGF2 mRNA variants induced high levels of human FGF2 protein using 1µg mRNA/ml at all time points assessed (Figure 5). Comparative analysis of IVT mRNA encoding for native human FGF2 and the variants showed an unexpected combined effect of codon optimization (i.e. CAI levels $\geq 0,76$) and an increase of GC content (GC content $\geq 51,7\%$) in the CDS of the mRNA. Figure. 5 shows BJ cells ($4 \cdot 10^4$ - $5 \cdot 10^4$ /well) transfected using IVT mRNAs complexed with TransIT mRNA transfection reagent (1µg mRNA/ml). Supernatants ($\geq n=2$ /condition) were obtained and subjected to human FGF2 specific protein ELISA (R and D systems). Values depicted are measured as pg/ml FGF2 protein.

Those sequences which were above the threshold of (CAI ≥ 0.76 and GC content $\geq 51,7\%$) were inducing significantly higher expression levels of FGF2 at early and late stages showing a surprisingly high benefit over native sequences in the amplitude and longevity of gene expression.

Example 6: Assessment of levels of human FGF7 protein by protein ELISA from cell culture supernatants of human BJ fibroblast cells up to 120h post transfection with human FGF7 IVT mRNA variants.

In order to assess whether codon optimization for optimal translation efficiency in the human system (CAI) and concomitant increase of GC content in the CDS of FGF7 mRNA variants changes expression of human FGF7 protein in human skin fibroblasts, B.J. fibroblasts were transfected with different FGF7 mRNA variants. mRNAs encoding SEQ ID NOs:1, 2 and 4 were used to transfect B.J. cells. Subsequently, the level of secretion of human FGF7 from transfected cells was determined for up to 120h post transfection.

Result: All 3 FGF7 mRNA variants are inducing high levels of human FGF7 protein using 1µg mRNA/ml at all time points assessed (Figure 6). Comparative analysis of IVT mRNA encoding for native human FGF7 and the variants showed an unexpected combined effect of codon optimization (i.e. CAI levels $\geq 0,74$) and an increase of GC content (GC content $\geq 39,5\%$) in the CDS of the mRNA. Figure 6 shows BJ cells ($4 \cdot 10^4$ - $5 \cdot 10^4$ /well) transfected using IVT mRNAs complexed with TransIT mRNA transfection reagent (1µg mRNA/ml). Supernatants were obtained and subjected to human FGF2 specific

protein ELISA (R and D systems). Values depicted are measured as pg/ml FGF2 protein.

Those sequences which were above the threshold of (CAI \geq 0.74 and GC content \geq 39,5%) were inducing significantly higher expression levels of FGF2 at early and late stages showing a surprisingly high benefit over native sequences in the amplitude and longevity of gene expression.

Example 7: Assessment of levels of human FGF2 protein by protein ELISA from cell culture supernatants of porcine epithelial sheets 24h to 72h post transfection with human FGF2 IVT mRNA variants.

In order to assess whether codon optimization for optimal translation efficiency in the human system (as determined by the CAI) and concomitant increase of GC content in the CDS of FGF2 mRNA variants changes expression of human FGF2 protein in porcine skin, epithelial sheets derived from porcine skin were transfected with different FGF2 mRNA variants. mRNAs encoding SEQ ID NOs:18, 19 and 21 were used to transfect epithelial sheets. TransIT alone as well as TransIT complexed to eGFP mRNA were used as controls. Subsequently, the level of secretion of human FGF2 from transfected tissues was determined for up to 72h post transfection.

Result: All 3 FGF2 mRNA variants induced high levels of human FGF2 protein using 1 μ g mRNA/ml at all time points assessed (Figure 7). Comparative analysis of IVT mRNA encoding for native human FGF2 and the variants showed an unexpected combined effect of codon optimization (i.e. CAI levels \geq 0,76) and an increase of GC content (GC content \geq 51,7%) in the CDS of the mRNA. Figure 7 shows porcine epithelial sheets transfected using IVT mRNAs complexed with TransIT mRNA transfection reagent (1 μ g mRNA/ml). Supernatants were obtained and subjected to human FGF2 specific protein ELISA (R and D systems). Values depicted are measured as pg/ml FGF2 protein.

Those sequences which were above the threshold of (CAI \geq 0.76 and GC content \geq 51,7%) were inducing significantly higher expression levels of FGF2 at early and late stages showing a surprisingly high benefit over native sequences in the amplitude and longevity of expression in an intact porcine tissue.

Example 8: Assessment of levels of human FGF7 protein by protein ELISA from cell culture supernatants of porcine epithelial sheets 24h to 72h post transfection with human FGF7 IVT mRNA variants.

In order to assess whether codon optimization for optimal translation efficiency in the human system (as determined by the CAI) and concomitant increase of GC content in the CDS of FGF7 mRNA variants changes expression of human FGF7 protein in porcine skin, epithelial sheets derived from porcine skin were transfected with different FGF7 mRNA variants. mRNAs encoding SEQ ID NOs:1, 2 and 4 were used to transfect epithelial sheets. TransIT alone as well as TransIT complexed to eGFP mRNA were used as controls. Subsequently, the level of secretion of human FGF7 from transfected tissues was determined for up to 72h post transfection.

Result: All 3 FGF7 mRNA variants are inducing high levels of human FGF7 protein using 1µg mRNA/well at all time points assessed (Figure 8). Comparative analysis of IVT mRNA encoding for native human FGF7 and the variants showed an unexpected combined effect of codon optimization (i.e. CAI levels ≥ 0.74) and an increase of GC content (GC content $\geq 39,5\%$) in the CDS of the mRNA. Figure 8 shows porcine epithelial sheets transfected using IVT mRNAs complexed with TransIT mRNA transfection reagent (1µg mRNA/ml). Supernatants were obtained and subjected to human FGF7 specific protein ELISA (R and D systems). Values depicted are measured as pg/ml FGF7 protein.

Those sequences which were above the threshold of (CAI ≥ 0.74 and GC content $\geq 39,5\%$) were inducing significantly higher expression levels of FGF7 at early and late stages showing a surprisingly high benefit over native sequences in the amplitude and longevity of expression in an intact porcine tissue.

Example 9: Detection of eGFP in porcine epithelial sheets 24h after transfection with eGFP IVT mRNA formulated using TransIT mRNA transfection reagent.

In this example eGFP expression was monitored over time as a positive control for transfection efficacy of experiments performed in example 7+8, respectively.

Porcine epithelial sheets were transfected with TransIT and TransIT complexed with eGFP mRNA as described above. In addi-

tion, a second formulation of TransIT and eGFP mRNA (0.5µg mRNA/ml) was included as a dosage control. Subsequently, eGFP protein expression in transfected tissue was monitored by direct fluorescence microscopy.

Result: similar levels of eGFP expression were detectable in both examples analysed showing comparability of transfection efficacies in both experiments (Figure 9). Importantly, a dose dependent effect of eGFP expression was detectable in this experiment.

Figure 9 shows eGFP mRNA formulated in TransIT used at different concentrations: 0.5 and 1µg mRNA/ml. Native organ samples were mounted 24h post transfection on Superfrost plus glass slides using Vectashield DAPI-Hard set embedding medium and subjected to direct fluorescence detection using a Zeiss AxioImage Z2 microscope with Apotome 2. Successful transfection was detected by eGFP positive cells in the epithelial sheets as compared to liposome only treated sheets.

Example 10: Detection of eGFP in porcine epithelial sheets 24h after transfection with eGFP IVT mRNA formulated using a liposomal transfection reagent.

In this example, eGFP expression induced by an alternative transfection formulation was monitored over time.

Porcine epithelial sheets were transfected with a liposome based formulation using two different eGFP mRNA concentrations (2µg/ml and 10µg/ml mRNA) as described above. Subsequently, eGFP protein expression in transfected tissue was monitored by direct fluorescence microscopy.

Result: eGFP expression was detectable in a dose dependent manner in this experiment (Figure 9 and Table 5). Overall transfection efficacy was comparable to results obtained in examples 7-9, respectively.

Table 5: eGFP expression in porcine epithelial sheets 24h post transfection

Formulation of mRNA	Amount (mRNA/dose)	eGFP expression in epidermis (pg/mg total protein)
Cationic amphiphilic	5.4µg/ml	775

liposome		
TransIT; lipoplex	2 μ g/ml	7677
Cationic liposome	2 μ g/ml	8363
Cationic liposome	10 μ g/ml	11180

Figure 10 shows eGFP mRNA formulated in liposomes used at two concentrations: 2 and 10 μ g mRNA/ml. 24h post transfection native organ samples were mounted on Superfrost plus glass slides using Vectashield DAPI-Hard set embedding medium and subjected to direct fluorescence detection using a Zeiss AxioImage Z2 microscope with Apotome 2. Successful transfection was detectable by concentration dependent increase in eGFP positive cells in the epithelial sheets as compared to liposome only treated sheets.

Example 11: Detection of whole mount β -Galactosidase (bGal) activity in porcine skin explants 24h after transfection with LacZ IVT mRNA formulated using a DOTAP based liposomal transfection reagent.

In order to assess whether mRNA variants are able to transfect mammalian skin in situ, punch biopsies obtained from porcine skin were transfected with different LacZ mRNA formulations. In this example LacZ expression induced by intradermal transfection was monitored by whole mount β -Galactosidase staining 24h post transfection.

Transfection of intact pig skin was done by direct, intradermal injection of the IVT mRNA solution (5 μ g mRNA/dose; +/- Rnase inhibitor). mRNA was formulated using DOTAP-liposomes. 24h post transfection organ samples were subjected to whole mount β -Galactosidase (bGal) staining. Successful transfection was detectable by BluoGal staining in situ. Subsequently, punch biopsies of the injected areas (8mm diameter) were taken, subcutaneous fat removed, and biopsies were cultured for 24h.

Result: LacZ expression was visualized by detection of bGal activity in transfected biopsies (Figure 11). bGal activity was comparable for different formulations of LacZ mRNA (+/- RNase inhibitor) and expression was detectable as seen by blue staining in the upper dermal compartment of transfected biopsies.

Example 12: Detection of eGFP expression in porcine skin explants 24h after transfection with eGFP IVT mRNA formulated using various transfection reagents and non-complexed RNAs.

In order to assess whether mRNA variants are able to transfect mammalian skin in situ, punch biopsies obtained from porcine skin were transfected with different eGFP mRNA formulations. In this example eGFP expression induced by intradermal transfection was monitored by eGFP protein ELISA from tissue extracts obtained 24h post transfection. Along these lines, different formulations of eGFP mRNA were produced and injected (see Table 6 for details).

Table 6: eGFP expression in porcine skin biopsies 24h post i.d. transfection

Formulation of mRNA	Amount (mRNA/dose)	eGFP expression in dermis
DOTAP based; liposomal	1-10µg	+
SAINT lipid based; liposomal	1-5µg	+
TransIT; lipoplex	1-10µg	+
Lipid-Nano-particle	1.2+2.4µg	+
Non-complexed	1-25µg	+

Formulations used included: eGFP mRNA complexed with TransIT mRNA transfection reagent, eGFP mRNA complexed with DOTAP based liposomal preparations, eGFP mRNA complexed with SAINT lipid based liposomal preparations, eGFP mRNA containing Lipid nanoparticles and as non-complexed eGFP mRNA formulated in physiologic buffer.

Transfection of intact pig skin was performed by direct, intradermal injection of the IVT mRNA solutions (the eGFP IVT mRNA (1-25µg mRNA/dose)). mRNA was formulated using TransIT mRNA transfection reagent, DOTAP based-liposomes, SAINT lipid based-liposomes, lipid nano-particles or non-complexed mRNA in physiologic buffer. Subsequently, punch biopsies of the injected areas (8mm diameter) were taken, subcutaneous fat removed, biopsies were cultured for 24h and analyzed for eGFP expression. 24h post transfection organ samples were subjected to protein extraction and subsequent eGFP protein ELISA.

Result: eGFP expression was detectable by eGFP protein ELISA 24h post injection. (Figure 12, Table 5). eGFP Lipoplexes (LNPs

and liposomal complexes) as well as TransIT (used as standard) showed similar concentration dependent eGFP induction. Optimal expression was detectable between 2.4µg and 5µg mRNA/dose. Non-complexed mRNA also showed successful transfection. However, the minimal concentration required in this experimental setting was 5µg mRNA/dose in order to induce detectable eGFP expression in porcine dermis showing less efficient transfection of mRNA in the absence of transfection reagents.

Example 13: Detection of Luciferase activity in porcine epithelial sheets 24h after transfection with FLuc IVT mRNA formulated using Trans IT and SAINT based liposomal transfection reagents.

In this example, FLuc expression induced by alternative transfection formulations was monitored over time.

Porcine epithelial sheets were transfected with Trans IT or a liposome based formulation using 2µg/ml mRNA as described above. Subsequently, Luciferase activity in transfected tissue was monitored by direct activity measurement.

Result: In this experiment, Luciferase activity was detectable in a lipid dose dependent manner (Figure 13 and Table 7). Overall transfection efficacy was comparable to results obtained in examples 7-10, respectively.

Table 7: Luciferase activity in porcine epithelial sheets 24h post transfection

Formulation of mRNA	Amount (mRNA/dose)	Luciferase activity (activity units)
Trans IT	0µg/ml	190
Saint based liposome 1 (low lipid formulation)	0µg/ml	174
Saint based liposome 2 (low lipid formulation)	0µg/ml	190
TransIT; lipoplex	2µg/ml	909047
Saint based liposome 1 (high lipid formulation)	2µg/ml	433383
Saint based liposome 1 (low lipid formulation)	2µg/ml	110871

Saint based liposome 2 (high lipid formulation)	2µg/ml	1018908
Saint based liposome 2 (low lipid formulation)	2µg/ml	910750

Figure 13 shows FLuc mRNA formulated in liposomes used at two lipid concentrations. 24h post transfection native organ samples were subjected to Firefly Luc One-Step Glow Assay Kit. Successful transfection was detectable by activity units (luminescence) and direct luminescence detection on a Gel-Doc system.

Example 14: Detection of Luciferase activity in porcine epithelial sheets and porcine dermal explants 24h after transfection with FLuc IVT mRNA formulated using Trans IT and SAINT based liposomal transfection reagents.

In this example, Firefly Luciferase expression induced by alternative transfection formulations was monitored over time.

Porcine epithelial sheets and dermal explants were transfected with Trans IT or a liposome based formulation using 2µg/ml mRNA as described above. Subsequently, Luciferase activity in transfected tissue was monitored by direct activity measurement.

Result: Luciferase activity was detectable in both, epithelial tissue as well as dermal tissue following transfection (Figure 14). Overall transfection efficacy was comparable to results obtained in examples 7-10, respectively.

Figure 14 shows FLuc mRNA formulated in liposomes used at two lipid concentrations. 24h post transfection native organ samples (i.e. epithelial sheets and dermal explants) were subjected to Firefly Luc One-Step Glow Assay Kit. Successful transfection was detectable by activity units (luminescence).

Example 15: Comparison of Seq ID NO:1 mRNAs to the mRNA variant containing 100% replacement of Pseudo-U for U and 5mC for C by assessment of levels of human FGF7 protein by protein ELISA from cell culture supernatants of murine 3T3 cells 24h to 120h post transfection.

In this example the effect of non-canonical/modified nucleotides (e.g.: pseudoU and m5C) on expression levels of FGF7 mRNA variants is assessed. Murine 3T3 cells were transfected with two

forms of native (SEQ ID NO:1) IVT mRNA (mRNA: 1µg/ml): one containing 100% replacement of Pseudo-U for U and 5mC for C (indicated as Seq ID1_mn) and one w/o modified nucleotides (Seq ID1). Again, TransIT alone was used as control. Subsequently, the level of secretion of human FGF7 from transfected tissue is determined for up to 120h post transfection.

Result: FGF7 expression is visualized by detection of secreted FGF7 in cell supernatants. As shown in Figure 15, both mRNA variants induce high level expression of FGF7 protein at all time points tested.

Those sequences which were devoid of modified nucleotides are inducing significantly higher expression levels of FGF7 at early and late stages showing a surprisingly high benefit over modified nucleotides in wt, native sequences in the amplitude and longevity of expression in murine cells and an intact porcine tissue.

Example 16: Analysis of Hyaluronic acid levels following treatment of murine 3T3 fibroblast cells with optimized FGF2 mRNA variants up to 120h post transfection

In order to assess whether FGF2 mRNA variants were able to modify hyaluronic acid (=hyaluronan) secretion in murine 3T3 fibroblasts over extended time periods, fibroblasts were transfected with different FGF2 mRNA variants and hyaluronic acid secretion was assessed for up to 120h post transfection.

mRNAs encoding SEQ ID NOs:18, 19 and 21 were used to transfect murine 3T3 cells. Again, TransIT alone was used as control. Subsequently, the level of secreted hyaluronan from the supernatant of transfected cells was determined for up to 120h post transfection using the Hyaluronan Quantikine ELISA Kit.

Result: All 3 FGF2 mRNA variants are inducing secretion of high levels of hyaluronan using 1µg mRNA/well at all time points assessed (Figure 16) showing bioactivity of the secreted FGF2 protein in this system and a high benefit in the amplitude of IVT mRNA induced hyaluronan synthesis in murine cells. Values depicted are measured as ng/ml hyaluronan.

Example 17: Analysis of Hyaluronic acid levels following treatment of murine 3T3 cells, porcine epithelial sheets and porcine fibroblast cells with optimized FGF mRNA variants up to 120h

post transfection

In order to assess whether FGF mRNA variants are able to modify hyaluronan secretion in murine cells, porcine epithelial sheets and primary porcine fibroblasts over extended time periods, sheets and fibroblasts are transfected with different FGF mRNA variants and hyaluronic acid secretion is assessed for up to 72h post transfection.

mRNAs encoding SEQ ID NOs:1, 2, 3, 4, 5, 18, 19, 20, 21 and 22, are used to transfect sheets and fibroblasts cells (1µg/ml). Subsequently, the level of secreted hyaluronic acid (i.e. newly synthesized) from the supernatant of transfected cells is determined for up to 120h post transfection using the Hyaluronan Quantikine ELISA Kit.

Result: IVT mRNA induced Hyaluronan synthesis is visualized by detection of hyaluronan in supernatants of murine and porcine cells and epithelial sheets (Figure 18-21 and data not shown). All FGF mRNA variants are inducing secretion of high levels of hyaluronic acid using 1µg mRNA/well at all time points assessed showing bioactivity of the secreted FGF protein in this system. Figure 18-21 show bioactivity of the secreted FGF2 and FGF7 proteins in the systems used and a high benefit in the amplitude of IVT mRNA induced hyaluronan synthesis in murine and porcine cells or tissue. Values depicted are measured as ng/ml hyaluronan.

Expression is also induced at a higher level than with using recombinant FGF2 or FGF7 protein stimulation in the culture medium, respectively. For example, pig fibroblasts (see Figure 18) cultured in the presence of recombinant FGF7 protein show a 12% increase in secreted Hyaluronan as compared to non-treated negative control cells. In contrast, IVT mRNA treated samples show a 58-70% increase. Similarly, also epithelial sheets treated with FGF7 encoding IVT mRNAs secrete 43-83% more Hyaluronan than untreated controls (Figure 19).

For FGF2 this effect is also prominent, with an increase of 43% following treatment with recombinant FGF2 protein in porcine fibroblasts (Figure 20). IVT encoded mRNAs encoding FGF2 show a more efficient Hyaluronan secretion with an increase of 117-136% compared to the untreated control samples. For FGF2 treated epithelial sheets a 23-71% increase can be detected accordingly (Figure 21).

Example 18: Assessment of levels of human FGF7 protein by protein ELISA from cell culture supernatants of porcine skin cells following transfection with human FGF7 IVT mRNA variants.

In order to assess whether codon optimization for optimal translation efficiency in the porcine system (as determined by the CAI) and concomitant increase of GC content in the CDS of FGF7 mRNA variants changes expression of human FGF7 protein in porcine skin cells, porcine primary skin fibroblasts were derived from porcine skin and were transfected with different FGF7 mRNA variants. mRNAs encoding SEQ ID NOs:1, 2 and 4 were used to transfect porcine cells. TransIT alone as well as TransIT complexed to eGFP mRNA were used as controls. Subsequently, the level of secretion of human FGF7 from transfected tissues was determined for up to 48h post transfection. Values depicted are measured as pg/ml FGF7 protein.

Result: All 3 FGF7 mRNA variants are inducing high levels of human FGF7 protein using 1µg mRNA/well at all time points assessed (Figure 22). Comparative analysis of IVT mRNA encoding for native human FGF7 and the variants showed an unexpected combined effect of codon optimization (i.e. CAI levels ≥ 0.74) and an increase of GC content (GC content $\geq 39,5\%$) in the CDS of the mRNA. Figure 22 shows porcine cells transfected using IVT mRNAs complexed with TransIT mRNA transfection reagent (1µg mRNA/ml). Supernatants were obtained and subjected to human FGF7 specific protein ELISA (R and D systems). Values depicted are measured as pg/ml FGF7 protein.

Those sequences which were above the threshold of (CAI ≥ 0.74 and GC content $\geq 39,5\%$) were inducing significantly higher expression levels of FGF7 at early and late stages showing a surprisingly high benefit over native sequences in the amplitude and longevity of expression in porcine cells.

Example 19: Assessment of levels of human FGF7 protein by protein ELISA from cell culture supernatants of murine 3T3 fibroblasts following transfection with human FGF7 IVT mRNA variants.

In this example, the effect of differential codon optimization for GC contents lower than the threshold (39,5%) and lower CAI levels (i.e. CAI < 0.74) in the coding sequence (CDS) of FGF7 mRNA variants is assessed and compared to different IVT mRNA

variants. 3T3 fibroblasts are transfected with native or optimized (SEQ ID NO:1 and SEQ ID NO:3), as well as variants displaying CAIs<0.74 and/or GC contents <39,5% (e.g.: SEQ ID NO:5) as described above. Again, TransIT alone is used as control. Subsequently, the level of secretion of human FGF7 from transfected cells is determined for up to 120h post transfection. Values depicted are measured as pg/ml FGF7 protein.

Result: FGF7 expression is visualized by detection of secreted FGF7 in cell supernatants.

Those sequences which are above the threshold of (CAI \geq 0.74 and GC content \geq 39,5%) are inducing significantly higher expression levels of FGF7 at early and late stages showing a surprisingly high benefit over wt, native sequences in the amplitude and longevity of expression in murine cells (see Figure 23), whereas sequences which underwent optimization but were below the threshold of (CAI \geq 0.74 and GC content \geq 39,5%) are less efficient in inducing FGF7 in cells than sequences above the threshold of (CAI \geq 0.74 and GC content \geq 39,5%, see Figure 24).

Example 20: Assessment of levels of human FGF7 protein by protein ELISA from cell culture supernatants of human skin fibroblasts following transfection with human FGF7 IVT mRNA variants.

In this example, the effect of differential codon optimization for GC contents lower than the threshold (39,5%) and lower CAI levels (i.e. CAI<0.74) in the coding sequence (CDS) of FGF7 mRNA variants is assessed and compared to different IVT mRNA variants. Human skin fibroblasts are transfected with native or optimized (SEQ ID NO:1 and SEQ ID NO:3), as well as variants displaying CAIs<0.74 and/or GC contents <39,5% (e.g.: SEQ ID NO:5) as described above. Again, TransIT alone is used as control. Subsequently, the level of secretion of human FGF7 from transfected cells is determined for up to 120h post transfection. Values depicted are measured as pg/ml FGF7 protein.

Result: FGF7 expression is visualized by detection of secreted FGF7 in cell supernatants.

Those sequences which are above the threshold of (CAI \geq 0.74 and GC content \geq 39,5%) are inducing significantly higher expression levels of FGF7 at early and late stages showing a surprisingly high benefit over wt, native sequences in the amplitude

and longevity of expression in human cells whereas sequences which underwent optimization but are below the threshold of (CAI \geq 0.74 and GC content \geq 39,5%) are less efficient in inducing FGF7 in human cells than sequences above the threshold of (CAI \geq 0.74 and GC content \geq 39,5%, see Figure 25).

Example 21: Assessment of levels of human FGF2 protein by protein ELISA from cell culture supernatants of porcine skin cells following transfection with human FGF2 IVT mRNA variants.

In this example, the effect of differential codon optimization for GC contents in the coding sequence (CDS) of FGF2 mRNA variants is assessed and compared to different IVT mRNA variants. Porcine skin cells are transfected with native or optimized (SEQ ID NO:18 and SEQ ID NO:19, SEQ ID NO:21), as well as variants displaying CAIs $<$ 0,76 and/or GC contents $<$ 51,7% (e.g.: SEQ ID NO:22) as described above. Subsequently, the level of secretion of human FGF2 from transfected tissue is determined for up to 48h post transfection.

Result: FGF2 expression is visualized by detection of secreted FGF2 in cell supernatants. Values depicted are measured as pg/ml FGF2 protein. All FGF2 mRNA variants induced high levels of human FGF2 protein using 1 μ g mRNA/ml at all time points assessed (Figure 26).

Those sequences which are above the threshold of (CAI \geq 0.76 and GC content \geq 51,7%) are inducing significantly higher expression levels of FGF2 at early and late stages showing a surprisingly high benefit over wt, native sequences in the amplitude and longevity of expression in an intact porcine tissue, whereas sequences which underwent optimization but are below the threshold of (CAI \geq 0.76 and GC content \geq 51,7%) are less efficient in inducing FGF2 in porcine cells.

Example 22: Assessment of levels of human FGF2 protein by protein ELISA from cell culture supernatants of murine 3T3 fibroblasts following transfection with human FGF2 IVT mRNA variants.

In this example, the effect of differential codon optimization for GC contents lower than the threshold (51,7%) and lower CAI levels (i.e. CAI $<$ 0.76) in the coding sequence (CDS) of FGF2 mRNA variants is assessed and compared to different IVT mRNA variants. 3T3 fibroblasts were transfected with native or opti-

mized (SEQ ID NO:18 and SEQ ID NO:20), as well as variants displaying CAIs<0.76 and/or GC contents <51,7% (e.g.: SEQ ID NO:22) as described above. Again, TransIT alone is used as control. Subsequently, the level of secretion of human FGF2 from transfected cells is determined for up to 120h post transfection.

Result: FGF2 expression is visualized by detection of secreted FGF2 in cell supernatants. Values depicted are measured as pg/ml FGF2 protein. All FGF2 mRNA variants induced high levels of human FGF2 protein using 1µg mRNA/ml at all time points assessed (Figure 27).

Those sequences which are above the threshold of (CAI≥0.76 and GC content ≥51,7%) are inducing significantly higher expression levels of FGF2 at early and late stages showing a surprisingly high benefit over wt, native sequences in the amplitude and longevity of expression in murine cells whereas sequences which underwent optimization but are below the threshold of (CAI≥0.76 and GC content ≥51,7%) are less efficient in inducing FGF2 in murine cells following transfection and long term culture.

Example 23: Assessment of levels of human FGF2 protein by protein ELISA from cell culture supernatants of human skin fibroblasts following transfection with human FGF2 IVT mRNA variants.

In this example, the effect of differential codon optimization for GC contents lower than the threshold (51,7%) and lower CAI levels (i.e. CAI<0.76) in the coding sequence (CDS) of FGF2 mRNA variants is assessed and compared to different IVT mRNA variants. Human skin fibroblasts are transfected with native or optimized (SEQ ID NO:18 and SEQ ID NO:20), as well as variants displaying CAIs<0.76 and/or GC contents <51,7% (e.g.: SEQ ID NO:22) as described above. Again, TransIT alone is used as control. Subsequently, the level of secretion of human FGF2 from transfected cells is determined for up to 120h post transfection.

Result: FGF2 expression is visualized by detection of secreted FGF2 in cell supernatants. Values depicted are measured as pg/ml FGF2 protein. All FGF2 mRNA variants induced high levels of human FGF2 protein using 1µg mRNA/ml at all time points assessed (Figure 28).

Those sequences which are above the threshold of (CAI \geq 0.76 and GC content \geq 51,7%) are inducing significantly higher expression levels of FGF2 at early and late stages showing a surprisingly high benefit over wt, native sequences in the amplitude and longevity of expression in human cells whereas sequences which underwent optimization but are below the threshold of (CAI \geq 0,76 and GC content \geq 51,7%) are less efficient in inducing FGF2 in human cells.

Example 24: Detection of mRNA encoding different FGF2 and FGF7 variants by FGF-variant specific quantitative Real Time-PCR from cDNA obtained from murine 3T3 fibroblast cells 24h-120h post transfection.

In order to assess whether FGF2 and FGF7 mRNA variants are stable in murine fibroblasts over prolonged time periods, different mRNAs encoding SEQ ID NOs:1-5 and 18-22 are used to transfect 3T3 cells. RNA is isolated at different time points (24-120h post transfection) and the presence of mRNA in transfected cells determined up to 120h post transfection by quantitative RT PCR.

Result: 3T3 cells transfected without mRNA, or with 1 μ g mRNA complexed with TransIT mRNA transfection reagent. Total cellular RNAs are isolated at different time points after transfection (24h-120h) and mRNAs are reverse transcribed into cDNA by conventional RT-PCR. cDNA samples are then subjected to variant specific quantitative real time PCR using primers for SEQ ID NOs:1-5 and 18-22 for the detection of transfected FGF2 and FGF7 mRNAs and appropriate PCR controls. It follows that there is differential stability of IVT mRNAs in cells according to CAI and G+C content.

Example 25: Detection of mRNA encoding different FGF2 and FGF7 variants by FGF-variant specific quantitative Real Time-PCR from cDNA obtained from human BJ fibroblast cells 24h-120h post transfection.

In order to assess whether FGF2 and FGF7 mRNA variants are stable in human skin fibroblasts over prolonged time periods, different mRNAs encoding SEQ ID NOs:1-5 and 18-22 are used to transfect 3T3 cells. RNA is isolated at different time points (24-120h post transfection) and the presence of mRNA in trans-

fectected cells determined up to 120h post transfection by quantitative RT PCR.

Result: BJ cells transfected without mRNA, or with 1µg mRNA complexed with TransIT mRNA transfection reagent. Total cellular RNAs are isolated at different time points after transfection (24h-120h) and mRNAs are reverse transcribed into cDNA by conventional RT-PCR. cDNA samples are then subjected to variant specific quantitative real time PCR using primers for SEQ ID NOs:1-5 and 18-22 for the detection of transfected FGF2 and FGF7 mRNAs and appropriate PCR controls. It follows that there is differential stability of IVT mRNAs in cells according to CAI and G+C content.

Example 26: Analysis of stability and activity of recombinant FGF proteins in comparison to IVT mRNA variant induced protein by ELISA.

In order to assess whether recombinant FGF2 or FGF7 protein are able to regulate FGF expression and subsequent activity in a similar manner as IVT mRNAs, murine 3T3 or porcine primary fibroblasts cells were either incubated in the presence of 1ng/ml recombinant FGF2 or FGF7 protein or were transfected with different FGF2 and FGF7 mRNA variants. mRNAs encoding SEQ ID NOs:1 and 2 and 18, 19 and 21 were used to transfect murine 3T3 cells and porcine primary fibroblast cells. Subsequently, the level of FGF2 and FGF7 protein was determined for 24h post transfection/addition of protein.

Result: FGF2 and FGF7 expression is visualized by detection of secreted FGF2 and FGF7 in cell supernatants by protein ELISA. As shown in Figure 17, both, recombinant FGF2 as well as recombinant FGF7 protein, are unstable over 24h in this experiment. In neither of the individual experiments performed, remaining FGF2 or FGF7 protein could be detected in the tissue culture supernatant of murine 3T3 - or porcine primary fibroblasts. In contrast IVT mRNA variants induced high FGF protein levels at the time of analysis in all experiments. In addition, this lack of detection also shows that no FGF2 or FGF7 protein was newly synthesized following recombinant FGF2/7 exposure. Importantly, this was also supported by the concomitant testing of detectability of porcine and murine FGFs by the human ELISA system: the ELISA systems employed were also able to detect murine and por-

cine FGFs. Thus, a lack of FGF signals in the ELISA shown is demonstrating that no feedback loop was initiated by the rec. proteins in these experiments in murine or porcine cells.

It follows that IVT mRNA variants as presented in this invention are surprisingly able to regulate FGF expression and activity/function in vertebrate cells differentially than recombinant FGF protein.

Accordingly, the present invention relates to the following preferred embodiments:

1. Fibroblast growth factor (FGF) messenger-RNA (mRNA), wherein the mRNA has a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region encoding human FGF2 or FGF7, a 3' untranslated region (3'-UTR) and a poly-adenosine Tail (poly-A tail), for use in the treatment of local skin hypotrophy conditions, wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 2 (FGF2) or wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 7 (FGF7).

2. FGF mRNA for use according to embodiment 1, wherein the local skin hypotrophy condition is selected from the group consisting of cutis laxa, acrodermatitis chronica atrophicans, atrophoderma idiopathica et progressiva Pasini Pierini, scars resulting from perforating dermatoses, atrophy blanche, necrobi-osis lipoidica, radiation dermatitis, striae cutis distensae, atrophic skin conditions, glucocorticoid (GC)-induced skin atrophy, atrophic scars, and skin ulcer.

3. FGF mRNA for use according to any one of embodiments 1 or 2, wherein the poly-A tail comprises at least 60 adenosine monophosphates, preferably at least 100 adenosine monophosphates, especially at least 120 adenosine monophosphates.

4. FGF mRNA for use according to any one of embodiments 1 to 3, wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR are different from the native FGF2 or FGF7 mRNA, preferably wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR contain at least one stabilisation sequence, preferably a stabilisation sequence with the general formula (C/U)CCAN_xCCC(U/A)Py_xUC(C/U)CC

(SEQ ID NO:38), wherein "x" is, independently in N_x and P_{y_x} , an integer of 0 to 10, preferably of 0 to 5, especially 0, 1, 2, 4 and/or 5).

5. FGF mRNA for use according to any one of embodiments 1 to 4, wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR are different from the native FGF2 or FGF7 mRNA, and contain at least one destabilisation sequence element (DSE), preferably AU-rich elements (AREs) and/or U-rich elements (UREs), especially a single, tandem or multiple or overlapping copies of the nonamer UUAUUUA(U/A)(U/A).

6. FGF mRNA for use according to any one of embodiments 1 to 5, wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR are different from the native FGF2 or FGF7 mRNA, and wherein the 5'-UTR and/or 3'-UTR are the 5'-UTR and/or 3'-UTR of a different human mRNA than FGF2 or FGF7, preferably selected from alpha Globin, beta Globin, Albumin, Lipoxxygenase, ALOX15, alpha(1) Collagen, Tyrosine Hydroxylase, ribosomal protein 32L, eukaryotic elongation factor 1a (EEF1A1), 5'-UTR element present in orthopoxvirus, and mixtures thereof, especially selected from alpha Globin, beta Globin, alpha(1) Collagen, and mixtures thereof.

7. FGF mRNA for use according to any one of embodiments 1 to 6, wherein in the FGF2 or FGF7 mRNA, at least 5%, preferably at least 10%, preferably at least 30%, especially at least 50% of all

- cytidine residues are replaced by 5-methyl-cytidine residues, and/or
- cytidine residues are replaced by 2-amino-2-deoxy-cytidine residues, and/or
- cytidine residues are replaced by 2-fluoro-2-deoxy-cytidine residues, and/or
- cytidine residues are replaced by 2-thio-cytidine residues, and/or
- cytidine residues are replaced by 5-iodo-cytidine residues, and/or
- uridine residues are replaced by pseudo-uridine residues,

and/or

- uridine residues are replaced by 1-methyl-pseudo-uridine residues, and/or
- uridine residues are replaced by 2-thio-uridine residues, and/or
- uridine residues are replaced by 5-methyl-uridine residues, and/or
- adenosine residues are replaced by N6-methyl-adenosine residues.

8. FGF mRNA for use according to any one of embodiments 1 to 7, wherein in the FGF2 or FGF7 mRNA, at least 5%, preferably at least 10%, preferably at least 30%, especially at least 50% of all

- cytidine residues are replaced by 5-methyl-cytidine residues, and/or
- uridine residues are replaced by pseudo-uridine residues, and/or
- uridine residues are replaced by 2-thio-uridine residues.

9. FGF mRNA for use according to any one of embodiments 1 to 8, wherein the FGF mRNA has a GC to AU ratio of at least 51.7%, preferably of at least 52%, more preferred 55%, even more preferred, at least 58%, especially at least 60% in case of the FGF2 mRNA and at least 39,5%, preferably of at least 43%, more preferred 45%, even more preferred, at least 50%, especially at least 55% in case of the FGF7 mRNA.

10. FGF mRNA for use according to any one of embodiments 1 to 9, wherein the FGF2 mRNA has a codon adaption index (CAI) of at least 0.77, preferably at least 0.8 and/or the FGF7 mRNA has a CAI of at least 0.75, preferably at least 0.77.

11. FGF mRNA for use according to any one of embodiments 1 to 10, wherein the coding region of the FGF mRNA encodes human FGF2 and is preferably SEQ ID NO:30, especially SEQ ID NO:31.

12. FGF mRNA for use according to any one of embodiments 1 to 10, wherein the coding region of the FGF mRNA encodes human FGF7 and is preferably SEQ ID NO:12, especially SEQ ID NOs:13.

13. FGF mRNA for use according to any one of embodiments 1 to 12, wherein the FGF mRNA is administered subcutaneously, intradermally, transdermally, epidermally, or topically, especially epidermally.
14. FGF mRNA for use according to any one of embodiments 1 to 13, wherein the FGF mRNA is administered at least twice within one month, preferably weekly.
15. FGF mRNA for use according to any one of embodiments 1 to 14, wherein the FGF mRNA is administered in an amount of 0.01µg to 100 mg per dose, preferably of 0.1µg to 10mg per dose, especially of 1µg to 1mg per dose.
16. Pharmaceutical formulation, preferably for use in the treatment of local skin hypotrophy conditions, preferably atrophic scars and glucocorticoid (GC)-induced skin atrophy, comprising the FGF mRNA as defined in any one of embodiments 1 to 15.
17. Pharmaceutical formulation, preferably for use according to embodiment 16, comprising a pharmaceutically acceptable carrier, preferably polymer based carriers, especially cationic polymers, including linear and branched PEI and viromers; lipid nanoparticles and liposomes, nanoliposomes, ceramide-containing nanoliposomes, proteoliposomes, cationic amphiphilic lipids e.g.: SAINT-Lipids, both natural and synthetically-derived exosomes, natural, synthetic and semi-synthetic lamellar bodies, nanoparticulates, calcium phosphor-silicate nanoparticulates, calcium phosphate nanoparticulates, silicon dioxide nanoparticulates, nanocrystalline particulates, semiconductor nanoparticulates, dry powders, poly(D-arginine), nanodendrimers, starch-based delivery systems, micelles, emulsions, sol-gels, niosomes, plasmids, viruses, calcium phosphate nucleotides, aptamers, peptides, peptide conjugates, vectorial tags, poly-lactic-co-glycolic acid (PLGA) polymers; preferably small-molecule targeted conjugates, or viral capsid proteins, preferably cationic polymers and liposomes, especially cationic polymers.

18. Pharmaceutical formulation for use according to embodiment 16 or 17, comprising cationic polymers including linear and branched PEI and viromers, lipid nanoparticles and liposomes, transfersomes, and nanoparticulates, preferably calcium phosphate nanoparticulates and cationic polymers, especially cationic polymers.

19. Pharmaceutical formulation for use according to embodiment 16, wherein the mRNA is non-complexed mRNA, and wherein preferably the non-complexed mRNA is contained in a suitable aqueous buffer solution, especially a physiological glucose buffered aqueous solution.

20. Pharmaceutical formulation for use according to any one of embodiments 16 to 19, wherein the formulation comprises a 1xHEPES buffered solution; a 1xPhosphate buffered solution, a Na-Citrate buffered solution; a Na-Acetate buffered solution; Ringer's lactate solution; preferably additionally comprising glucose, especially 5% Glucose.

21. Pharmaceutical formulation for use according to any one of embodiments 16 to 20, wherein the formulation comprises FGF2 and FGF7 mRNAs as defined in any one of embodiments 1 to 15.

22. Kit for administering the FGF mRNA for use according to any one of embodiments 1 to 15 to a patient comprising

- the FGF2 and/or FGF7 mRNA as defined in any one of embodiments 1 to 15, and
- a skin delivery device.

23. Kit according to embodiment 22, wherein the skin delivery device is an intradermal delivery device, preferably selected from the group consisting of needle based injection systems.

24. Kit according to embodiment 22, wherein the skin delivery device is a transdermal delivery device, preferably selected from the group consisting of transdermal patches, hollow and solid microneedle systems, microstructured transdermal systems, electrophoresis systems, and iontophoresis systems.

25. Kit according to embodiment 22, wherein the skin delivery device is an epidermal delivery device, preferably selected from the group consisting of needle free injection systems, laser based systems, especially Erbium YAG laser systems, and gene gun systems.

26. Method for treating local skin hypotrophy conditions, preferably atrophic scars and glucocorticoid (GC)-induced skin atrophy, wherein the FGF2 mRNA and/or FGF7 mRNA as defined in any one of embodiments 1 to 15 is administered in an effective amount to a patient in need thereof.

27. Cosmetic skin care method wherein a FGF messenger-RNA (mRNA) is contacted with the human skin, wherein the mRNA has a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region encoding human FGF, a 3' untranslated region (3'-UTR) and a poly-adenosine Tail (poly-A tail), wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 2 (FGF2) or wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 7 (FGF7).

28. Cosmetic skin care method according to embodiment 27, wherein the skin is an ageing skin.

29. Cosmetic skin care method according to embodiment 27 or 28, wherein the FGF mRNA molecule is defined as in any one of embodiments 3 to 11.

30. Cosmetic formulation comprising an FGF mRNA, wherein the mRNA has a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region encoding human FGF, a 3' untranslated region (3'-UTR) and a poly-adenosine Tail (poly-A tail), wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 2 (FGF2) or wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 7 (FGF7), and a cosmetic carrier.

31. Cosmetic formulation according to embodiment 30, wherein the FGF mRNA molecule is defined as in any one of embodiments 3 to 11.

32. Cosmetic formulation according to embodiment 30 or 31, wherein the cosmetic carrier is an ointment, a gel, especially a hydrogel, a liposome, nano/microparticles, or an emulsion.

Claims

1. Fibroblast growth factor (FGF) messenger-RNA (mRNA), wherein the mRNA has a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region encoding human FGF, a 3' untranslated region (3'-UTR) and a poly-adenosine Tail (poly-A tail), for use in the treatment of local skin hypotrophy conditions, wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 2 (FGF2) or wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 7 (FGF7).
2. FGF mRNA for use according to claims 1, wherein the local skin hypotrophy condition is selected from the group consisting of cutis laxa, acrodermatitis chronica atrophicans, atrophoderma idiopathica et progressiva Pasini Pierini, scars resulting from perforating dermatoses, atrophy blanche, necrobiosis lipoidica, radiation dermatitis, striae cutis distensae, atrophic skin conditions, glucocorticoid (GC)-induced skin atrophy, atrophic scars and skin ulcer.
3. FGF mRNA for use according to claim 1 or 2, wherein the poly-A tail comprises at least 60 adenosine monophosphates, preferably at least 100 adenosine monophosphates, especially at least 120 adenosine monophosphates.
4. FGF mRNA for use according to any one of claims 1 to 3, wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR are different from the native FGF2 or FGF7 mRNA, preferably wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR contain at least one stabilisation sequence, preferably a stabilisation sequence with the general formula (C/U)CCAN_xCCC(U/A)Py_xUC(C/U)CC (SEQ ID NO:38), wherein "x" is, independently in N_x and Py_x, an integer of 0 to 10, preferably of 0 to 5, especially 0, 1, 2, 4 and/or 5.
5. FGF mRNA for use according to any one of claims 1 to 4, wherein the 5'-UTR or 3'-UTR or the 5'-UTR and the 3'-UTR are different from the native FGF2 or FGF7 mRNA, and wherein the 5'-UTR and/or 3'-UTR are the 5'-UTR and/or 3'-UTR of a different

human mRNA than FGF, preferably selected from alpha Globin, beta Globin, Albumin, Lipoxygenase, ALOX15, alpha(1) Collagen, Tyrosine Hydroxylase, ribosomal protein 32L, eukaryotic elongation factor 1a (EEF1A1), 5'-UTR element present in orthopoxvirus, and mixtures thereof, especially selected from alpha Globin, beta Globin, alpha(1) Collagen, and mixtures thereof.

6. FGF mRNA for use according to any one of claims 1 to 5, wherein the FGF mRNA has a GC to AU ratio of at least 51.7%, preferably of at least 52%, more preferred 55%, even more preferred, at least 58%, especially at least 60% in case of the FGF2 mRNA and at least 39,5%, preferably of at least 43%, more preferred 45%, even more preferred, at least 50%, especially at least 55% in case of the FGF7 mRNA.

7. FGF mRNA for use according to any one of claims 1 to 6, wherein the FGF2 mRNA has a codon adaption index (CAI) of at least 0.77, preferably at least 0.8 and/or the FGF7 mRNA has a CAI of at least 0.75, preferably at least 0.77.

8. FGF mRNA for use according to any one of claims 1 to 7, wherein the FGF2-encoding mRNA is preferably SEQ ID NO:30, especially SEQ ID NOs:31; and/or wherein the FGF7-encoding mRNA is preferably SEQ ID NO:12, especially SEQ ID NOs:13.

9. FGF mRNA for use according to any one of claims 1 to 8, wherein the FGF mRNA is administered subcutaneously, intradermally, transdermally, epidermally, or topically, especially epidermally.

10. Pharmaceutical formulation, especially for use in the treatment of local skin hypotrophy conditions, preferably atrophic scars and glucocorticoid (GC)-induced skin atrophy, comprising the FGF2 mRNA and/or FGF7 mRNA as defined in any one of claims 1 to 9.

11. Pharmaceutical formulation for use according to claim 10, comprising a pharmaceutically acceptable carrier, preferably polymer based carriers, especially cationic polymers, including

linear and branched PEI and viromers; lipid nanoparticles and liposomes, nanoliposomes, ceramide-containing nanoliposomes, proteoliposomes, cationic amphiphilic lipids e.g.: SAINT-Lipids, both natural and synthetically-derived exosomes, natural, synthetic and semi-synthetic lamellar bodies, nanoparticulates, calcium phosphor-silicate nanoparticulates, calcium phosphate nanoparticulates, silicon dioxide nanoparticulates, nanocrystalline particulates, semiconductor nanoparticulates, dry powders, poly(D-arginine), nanodendrimers, starch-based delivery systems, micelles, emulsions, sol-gels, niosomes, plasmids, viruses, calcium phosphate nucleotides, aptamers, peptides, peptide conjugates, vectorial tags, preferably small-molecule targeted conjugates, or viral capsid proteins, poly-lactic-co-glycolic acid (PLGA) polymers; preferably cationic polymers and liposomes, especially cationic polymers.

12. Kit for administering the FGF mRNAs for use according to any one of claims 1 to 9 to a patient comprising

- the FGF2 and/or FGF7 mRNA as defined in any one of claims 1 to 9, and
- a skin delivery device.

13. Kit according to claim 12, wherein the skin delivery device is

- an intradermal delivery device, preferably selected from the group consisting of needle based injection systems, or
- a transdermal delivery device, preferably selected from the group consisting of transdermal patches, hollow and solid microneedle systems, microstructured transdermal systems, electrophoresis systems, and iontophoresis systems, or
- an epidermal delivery device, preferably selected from the group consisting of needle free injection systems, laser based systems, especially Erbium YAG laser systems, and gene gun systems.


14. Method for treating local skin hypotrophy conditions, preferably atrophic scars and glucocorticoid (GC)-induced skin atrophy, wherein the FGF2 mRNA and/or FGF7 mRNA as defined in any one of claims 1 to 9 is administered in an effective amount to a patient in need thereof.

15. Cosmetic skin care method, especially for the ageing skin, wherein a FGF messenger-RNA (mRNA) is contacted with the human skin, wherein the mRNA has a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region encoding human FGF, a 3' untranslated region (3'-UTR) and a poly-adenosine Tail (poly-A tail), wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 2 (FGF2) or wherein the coding region of the FGF mRNA encodes for human fibroblast growth factor 7 (FGF7).

Fig. 1




Fig. 2



A

Fig. 3



B






Fig. 4



A

Fig. 5



B





Fig. 6



7/28

Fig. 7






Fig. 8




Fig. 9





Fig. 10








Fig. 11




12/28

Fig. 13


A




B



A



B






Fig. 15








Fig. 16

A



B

C



D

18/28




Fig. 18




Fig. 19




Fig. 20




Fig. 21

22/28




Fig. 22

23/28




Fig. 23

24/28




Fig. 24

25/28




Fig. 25

26/28




Fig. 26




Fig. 27




Fig. 28

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2018/070712

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K38/18 A61P17/00 A61P17/02
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61K A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, EMBASE, FSTA, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/071834 A1 (MURRAY MARY THERESA [US] ET AL) 13 June 2002 (2002-06-13) paragraphs [0003], [0028], [0039] - [0040]; claims 1-42 -----	1-15
X	WO 2015/117021 A1 (FACTOR BIOSCIENCE INC [US]) 6 August 2015 (2015-08-06) cited in the application page 48, line 11 - page 49, line 11 (page 3, lines 23-26; claim 202; examples 38,50, 34,35, 30 -----	1-15
X	WO 2014/089486 A1 (SHIRE HUMAN GENETIC THERAPIES [US]) 12 June 2014 (2014-06-12) cited in the application row 16 in the table on page 60 row 19 in the table on page 55; claim 1, -----	10-12
	-/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 26 September 2018	Date of mailing of the international search report 09/10/2018
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Habedanck, Robert

INTERNATIONAL SEARCH REPORT

 International application No
 PCT/EP2018/070712

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>LIN M P ET AL: "Electroporation improves transfection efficiency in rat wound healing model", JOURNAL OF THE AMERICAN COLLEGE OF SURGE, COLLEGE, CHICAGO, IL, US, vol. 199, no. 3, 1 September 2004 (2004-09-01), pages 58-59, XP004595076, ISSN: 1072-7515, DOI: 10.1016/J.JAMCOLLSURG.2004.05.120 abstract</p> <p style="text-align: center;">-----</p>	1-15
A	<p>CHUNQING DOU ET AL: "Strengthening the Skin with Topical Delivery of Keratinocyte Growth Factor-1 Using a Novel DNA Plasmid", MOLECULAR THERAPY, vol. 22, no. 4, 1 April 2014 (2014-04-01), pages 752-761, XP055427375, US ISSN: 1525-0016, DOI: 10.1038/mt.2014.2 abstract</p> <p style="text-align: center;">-----</p>	1-15
A	<p>G MARTI ET AL: "Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model", GENE THERAPY, vol. 11, no. 24, 1 December 2004 (2004-12-01), pages 1780-1785, XP055427408, GB ISSN: 0969-7128, DOI: 10.1038/sj.gt.3302383 abstract</p> <p style="text-align: center;">-----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2018/070712

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002071834 A1	13-06-2002	US 2002071834 A1 US 2007149475 A1	13-06-2002 28-06-2007

WO 2015117021 A1	06-08-2015	AU 2015210769 A1 BR 112016017736 A2 CA 2937036 A1 CN 105940110 A EP 3099801 A1 JP 2017510542 A KR 20160113121 A RU 2016131251 A US 2016324934 A1 US 2018021412 A1 WO 2015117021 A1	02-06-2016 10-10-2017 06-08-2015 14-09-2016 07-12-2016 13-04-2017 28-09-2016 01-03-2018 10-11-2016 25-01-2018 06-08-2015

WO 2014089486 A1	12-06-2014	EP 2929035 A1 US 2015366997 A1 WO 2014089486 A1	14-10-2015 24-12-2015 12-06-2014
